Page last updated: 2024-11-04

clofibrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Clofibrate is a lipid-lowering drug that was once widely used to treat high cholesterol. It is a fibrate derivative, a class of drugs that activate peroxisome proliferator-activated receptor alpha (PPARα). PPARα is a nuclear receptor that regulates lipid metabolism. When activated, PPARα stimulates the expression of genes involved in the breakdown of fatty acids and the synthesis of cholesterol. Clofibrate was synthesized in the 1960s and was initially marketed as an anti-inflammatory agent. However, it was soon discovered that clofibrate had significant lipid-lowering effects. Clofibrate reduces low-density lipoprotein (LDL) cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. It also lowers triglyceride levels. Clofibrate was once a popular treatment for high cholesterol, but its use has declined in recent years due to concerns about its safety. Clofibrate has been linked to an increased risk of gallstones, muscle damage, and liver problems. It has also been associated with an increased risk of cancer, although this finding is controversial. Clofibrate is no longer commonly used for the treatment of high cholesterol, but it is still studied for its potential therapeutic effects in other conditions, such as diabetes, obesity, and inflammatory bowel disease.'

angiokapsul: contains clofibrate & insoitolnicotinate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2796
CHEMBL ID565
CHEBI ID3750
SCHEMBL ID2356
MeSH IDM0004582

Synonyms (338)

Synonym
BIDD:GT0172
BIDD:PXR0178
clofibrate (clof)
CBIOL_001860
hpn91k7fu3 ,
unii-hpn91k7fu3
clofibrate [usan:usp:inn:ban:jan]
AB00052358-08
AB00052358-07
gtpl2667
propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, ethyl ester
KBIO1_000926
DIVK1C_000822
DIVK1C_000926
KBIO1_000822
NCI60_041748
ethyl 2-[(4-chlorophenyl)oxy]-2-methylpropanoate
artevil
einecs 211-277-4
clofibric acid, ethyl ester
sklero-tabuls
clofibrato [inn-spanish]
clofibrato [spanish]
ethyl-alpha-p-chlorophenoxy-isobutyrate
ethyl alpha-(p-chlorophenoxy)-alpha-methylpropionate
propionic acid, 2-(p-chlorophenoxy)-2-methyl-, ethyl ester
regelan n
hsdb 3038
skerolip
scrobin
normolipol
ethyl alpha-(4-chlorophenoxy)isobutyrate
misclerone
clofibratum [inn-latin]
nsc 79389
propionic acid, 2-(4-chlorophenoxy)-2-methyl-, ethyl ester
negalip
ccris 177
ethyl para-chlorophenoxyisobutyrate
cloberat
ethyl 2-(para-chlorophenoxy)-2-methylpropionate (iupac)
isobutyric acid, alpha-(p-chlorophenoxy)-, ethyl ester
abitrate
yoclo
ethyl alpha-(p-chlorophenoxy)isobutyrate
acetic acid, (p-chlorophenoxy)dimethyl-, ethyl ester
brn 1913459
propanoic acid, 2-(p-chlorophenoxy)-2-methyl-, ethyl ester
ethyl alpha-(4-chlorophenoxy)-alpha-methylpropionate
robigram
EU-0100306
clofibrate, liquid
SPECTRUM_001735
IDI1_000926
IDI1_000822
CHEBI:3750 ,
alpha-p-chlorophenoxyisobutyryl ethyl ester
2-(4-chlorophenoxy)-2-methylpropanoic acid ethyl ester
alpha-(p-chlorophenoxy)isobutyric acid, ethyl ester
NCGC00015257-01
BIO2_000297
lopac-c-6643
BIO2_000777
BIO1_000146
BIO1_000635
BIO1_001124
LOPAC0_000306
19 more names available
delipid
citiflus
liprinal
epib
azionyl
clofipront
ateriosan
persantinat
lipofacton
normet
normalip
amotril s
bresit
deliva
lipide 500
liposid
ethyl 2-(p-chlorophenoxy)-2-methylpropionate
ethyl .alpha.-(4-chlorophenoxy)isobutyrate
athranid-wirkstoff
normat
lobetrin
klofibrat
liponorm
nsc79389
arterosol
neo-atomid
gerastop
oxan 600
xyduril
skleromexe
apolan
recolip
atromida
sklero
clobren-5f
liporil
regelan
2-(p-chlorophenoxy)-2-methylpropionic acid ethyl ester
lipavlon
ethyl .alpha.-(p-chlorophenoxy)isobutyrate
ethyl .alpha.-(p-chlorophenoxy)-.alpha.-methylpropionate
atromid
ethyl p-chlorophenoxyisobutyrate
ethyl clofibrate
clobrat
atromid s
clobren-sf
ateculon
lipidsenker
atrovis
.alpha.-p-chlorophenoxyisobutyryl ethyl ester
klofiran
atromid-s
ethyl .alpha.-p-(chlorophenoxy)isobutyrate
clofibram
levatrom
lipamid
clofibate
ay-61123
miscleron
ay 61123
clofar
cartagyl
ethyl 2-(4-chlorophenoxy)-2-methylpropionate
amotril
lipavil
athebrate
ticlobran
elpi
atheropront
clofibratum
atheromide
fibralem
antilipid
serotinex
hyclorate
antilipide
atromidin
ethyl 2-(p-chlorophenoxy)isobutyrate
liporeduct
atrolen
clofibrat
clofibrato
cinnarizin
neo-atromid
angiokapsul
wln: gr dox1&1&vo2
ethyl chlorophenoxyisobutyrate
lipomid
claripex cpib
anparton
nsc-79389
.alpha.-(p-chlorophenoxy)isobutyric acid, ethyl ester
arterioflexin
chlorphenisate
dura clofibrat
regardin
ethyl .alpha.-(4-chlorophenoxy)-.alpha.-methylpropionate
claripex
bioscleran
liprin
clofinit
sklero-tablinen
ici 28257
ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
ethyl 2-(4-chlorophenoxy)-2-methyl-propanoate
acetic acid, (p-chlorophenoxy)dimethyl-, ethyl este
SPECTRUM5_001133
BCBCMAP01_000104
BSPBIO_001577
ici-28257
UPCMLD-DP019:001
cpib
CLOFIBRATE ,
637-07-0
C06916
DB00636
UPCMLD-DP019
clofibrate (jp17/usp/inn)
D00279
atromid-s (tn)
NCGC00093755-04
NCGC00093755-07
NCGC00093755-06
NCGC00093755-08
NCGC00093755-03
KBIO2_007351
KBIO2_005433
KBIO3_000593
KBIO2_004783
KBIOGR_000297
KBIOSS_000297
KBIOGR_000885
KBIO2_002215
KBIOSS_002215
KBIO2_000297
KBIO3_000594
KBIO2_002865
SPECTRUM4_000223
NINDS_000926
SPBIO_000998
NINDS_000822
SPECTRUM2_001209
NCIOPEN2_004739
IDI1_034047
NCGC00093755-05
NCGC00093755-01
chlorophenoxyisobutyrate, ethyl
MLS001336011
MLS001336012
MLS002153494
smr000058279
NCGC00015257-02
HMS1989O19
C 6643 ,
HMS2089P03
HMS2093G07
2-(4-chlorophenoxy)isobutyric acid ethyl ester
ethyl 2-(4-chlorophenoxy)isobutyrate
NCGC00015257-09
bdbm50085047
CHEMBL565 ,
chlorfenisate
BML2-F02 ,
HMS502J04
HMS1361O19
HMS502O08
HMS1791O19
FT-0665112
NCGC00015257-08
A834483
ethyl 2-(4-chloranylphenoxy)-2-methyl-propanoate
HMS3260N14
tox21_202414
tox21_300277
NCGC00254073-01
NCGC00259963-01
pharmakon1600-01503429
nsc-758474
nsc758474
dtxcid70336
dtxsid3020336 ,
cas-637-07-0
tox21_110116
HMS2233C17
CCG-40281
NCGC00015257-12
NCGC00015257-11
NCGC00015257-06
NCGC00015257-03
NCGC00015257-07
NCGC00015257-05
NCGC00015257-10
NCGC00015257-04
serofinex
sklerepmexe
vincamin compositum
sklero-tablinene
sklerolip
skleromex
FT-0625865
LP00306
AKOS015889383
clofibrate [mart.]
clofibrate [mi]
clofibrate [vandf]
clofibrate [ep monograph]
clofibrate [usan]
clofibrate [orange book]
clofibrate [hsdb]
clofibrate [jan]
clofibrate [inn]
clofibrate [who-dd]
clofibrate [iarc]
clofibrate [usp impurity]
HMS3373C06
HY-B0287
SCHEMBL2356
NCGC00015257-14
tox21_110116_1
NCGC00260991-01
tox21_500306
2-(4-chloro-phenoxy)-2-methyl-propionic acid ethyl ester
ethyl 2-(4-chlorophenoxy)-2-methylpropanoate #
p-chlorophenoxyisobutyric acid ethyl ester
isobutyric acid, .alpha.-(p-chlorophenoxy)-, ethyl ester
2-(p-chlorophenoxy)isobutyric acid ethyl ester
clobren sf
AC-33179
HMS3402O19
AB00052358_09
AB00052358_10
mfcd00000615
clofibrate, european pharmacopoeia (ep) reference standard
sr-01000075544
SR-01000075544-4
clofibrate, >=98.0% (gc)
clofibrate, analytical reference material
ethyl 2-(4-chlorophenoxy)-2-methylpropionate, 99%
clofibrate, united states pharmacopeia (usp) reference standard
Z53835984
SR-01000075544-1
SR-01000075544-5
SR-01000075544-8
SBI-0050294.P003
HMS3715J03
F20382
Q2701912
AS-14127
2-(p-chlorophenoxy)-2-methylpropanoic acid ethyl ester
M01536
SDCCGSBI-0050294.P004
NCGC00015257-22
S1820
ethyl2-(4-chlorophenoxy)-2-methylpropanoate
EN300-119182
clofibrate 100 microg/ml in acetonitrile
clofibrate (iarc)
clofibratum (inn-latin)
clofibrate (usan:usp:inn:ban:jan)
clofibrate (mart.)
clofibrate (ep monograph)
ethyl p-chlorophenoxyisobyturate
CS-0695012
c10ab01
HY-B0287R
clofibrato (inn-spanish)
clofibrate (standard)
clofibrate (usp impurity)
SY050795

Research Excerpts

Overview

Clofibrate is a known liver carcinogen specific to rodents. It has been shown to yield negative results in many in vitro genotoxicity and carcinogenicity tests in monkeys. It is an effective adjunctive drug in neonatal hyperbilirubinemia.

ExcerptReferenceRelevance
"Clofibrate is a known rodent hepatotoxicant classically associated with hepatocellular hypertrophy and increased serum activities of cellular alanine aminotransferase/aspartate aminotransferase (ALT/AST) in the absence of microscopic hepatocellular degeneration. "( Assessment of Preclinical Liver and Skeletal Muscle Biomarkers Following Clofibrate Administration in Wistar Rats.
Bánfai, B; Bennecke, M; Christen, F; Festag, M; Lenz, B; Maliver, P; Winter, M, 2017
)
2.13
"Clofibrate is a known liver carcinogen specific to rodents and has been shown to yield negative results in many in vitro genotoxicity and carcinogenicity tests in monkeys."( Repeated dose liver micronucleus assay using clofibrate in young adult rats.
Fujii, W; Hori, H; Kawasako, K; Takashima, R; Takayanagi, T; Tanaka, Y; Wako, Y, 2015
)
1.4
"Clofibrate is an effective adjunctive drug in neonatal hyperbilirubinemia, which results in decreased TSB level and reduced duration of phototherapy in late pre-term newborns."( The effect of clofibrate with phototherapy in late pre-term newborns with non-hemolytic jaundice.
Gharehbaghi, MM; Rahbani, ME; Sakha, SH, 2009
)
2.16
"Clofibrate is a glucuronosyl transferase inducer that has been proposed to increase the elimination of bilirubin in neonates with hyperbilirubinemia. "( The effect of clofibrate on hyperbilirubinemia of term neonates.
Ahmadabadi, F; Ayazi, P; Habibi, M; Javadi, A; Mahyar, A, 2012
)
2.18
"Clofibrate is a specific ligand of the peroxisome proliferator-activated receptor (PPAR); it activates PPAR which then binds to a peroxisome proliferator response element (PPRE) to induce the transcriptional initiation of genes primarily involved in lipid homeostasis."( Tissue-specific differential induction of duplicated fatty acid-binding protein genes by the peroxisome proliferator, clofibrate, in zebrafish (Danio rerio).
Denovan-Wright, EM; Lall, SP; Venkatachalam, AB; Wright, JM, 2012
)
1.31
"Clofibrate is a hypolipidemic drug belonging to the peroxisome proliferator (PP) family. "( Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: role of HMG-CoA reductase.
Autelli, R; Baccino, FM; Bonelli, G; Canuto, RA; Costelli, P; Maggiora, M; Martinasso, G; Muzio, G; Trombetta, A, 2003
)
2.08
"Clofibrate is a lipid-profile modifying agent belonging to the fibrate class of drugs. "( Synthesis and biological evaluation of new clofibrate analogues as potential PPARalpha agonists.
Dell'Uomo, N; Giannessi, F; Milazzo, FM; Perrone, MG; Santandrea, E; Sciarroni, AF; Scilimati, A; Tortorella, V, 2005
)
2.03
"Clofibrate is a glucuronosyl transferase inducer that has been proposed to increase the elimination of bilirubin in neonates with hyperbilirubinemia. "( Effect of clofibrate in jaundiced term newborns.
Farhat, ASh; Iranpour, R; Mohammadzadeh, A, 2005
)
2.17
"Clofibrate is a peroxisome proliferator known to induce liver tumours in rats. "( Proteomic characterization of the effects of clofibrate on protein expression in rat liver.
Boitier, E; Charbonnier, A; Courcol, M; Duchesne, M; Gautier, JC; Genet, B; Léonard, JF; Mariet, C; Parker, F; Roberts, R; Supatto, F, 2006
)
2.04
"Clofibrate is a hypolipidemic agent that causes muscle protein breakdown in rats, and an acute muscular syndrome in man. "( Clofibrate does not alter cyclic nucleotide metabolism in muscle.
Adibi, SA; Gindler, JS; Lehotay, DC; Levey, GS; Paul, HS, 1983
)
3.15
"Clofibrate (CPIB) is a drug applied as an antilipidaemic agent in mammals. "( Effect of clofibrate on the growth-kinetics of the murine P 1798(sc) lymphoma.
Faro, J; Puentes, E; Regueiro, BJ; Seoane, R; Ubeira, FM, 1983
)
2.11
"Clofibrate is a member of a class of cholesterotropic and cuprotropic chemicals."( Clofibrate hypocholesterolemia associated with increased hepatic copper.
Klevay, LM, 1983
)
2.43
"Clofibrate, which is a potent peroxisome proliferator and structurally unrelated to oleic acid, also conferred similar protease resistance upon the protein."( Evidence for conformational change of fatty acid-binding protein accompanying binding of hydrophobic ligands.
Honma, Y; Niimi, M; Odani, S; Takahashi, Y; Uchiumi, T, 1994
)
1.01
"Clofibrate is a better enhancer of glucuronosyl transferase induction than phenobarbital and causes 100% increase of hepatic bilirubin clearance within 6 hours."( [Pharmacologic treatment of neonatal jaundice. A new approach].
Gabilan, JC, 1998
)
1.02
"Clofibrate is a peroxisome proliferator that can cause hepatic cancer in rodents. "( Mitochondrial damage by the "pro-oxidant" peroxisomal proliferator clofibrate.
Halliwell, B; Li, QT; Ong, CN; Qu, B; Wong, KP, 1999
)
1.98
"Clofibrate appears to be an inhibitor of C biosynthesis."( Nonisotopic method for estimating cholesterogenesis in the rat.
Phillips, WA; Ratchford, JM; Schulta, JR, 1976
)
0.98
"4 Clofibrate may prove to be a useful adjunct to the treatment of maturity onset diabetes."( Effect of clofibrate on glucose tolerance in maturity onset diabetes.
Barnett, D; Craig, JG; Robinson, DS; Rogers, MP, 1977
)
1.22
"Clofibrate is a drug used commonly by persons in the age group requesting face lifts."( Latrogenic platelet dysfunction: an emerging peril.
Lian, EC; Wolfe, SA, 1975
)
0.98
"Clofibrate is known to be an inducer of alcohol- and acetaldehyde dehydrogenase. "( Enhancement of voluntary alcohol consumption in rats by clofibrate feeding.
Schlicht, I,
)
1.82

Effects

Clofibrate (Atromid-S) has been found to inhibit the contractility of isolated rabbit aortic muscle rings produced by exposure to norepinephrine, histamine or angiotensin. It has been considered to be a relatively safe antidiuretic in the treatment of diabetes insipidus.

ExcerptReferenceRelevance
"Clofibrate has an acute salutary effect on endothelium-dependent vasodilation in saline-treated rats, probably mediated through vascular calcium-activated potassium channels and independent of an antihypertensive effect."( Clofibrate acutely reverses saline-induced endothelial dysfunction: role of calcium-activated potassium channels.
Desai, KM; Sankaralingam, S; Wilson, TW, 2006
)
3.22
"Clofibrate has proven anticarcinogenic effects attributed to peroxisome proliferator-activated receptor alpha (PPARα) agonism, also affecting WNT-associated signaling molecules."( Clofibrate Demonstrates Efficacy in In Vitro Treatment of Lymphoma and Multiple Myeloma.
Schmeel, FC; Schmeel, LC; Schmidt-Wolf, IG, 2016
)
2.6
"Clofibrate has an acute salutary effect on endothelium-dependent vasodilation in saline-treated rats, probably mediated through vascular calcium-activated potassium channels and independent of an antihypertensive effect."( Clofibrate acutely reverses saline-induced endothelial dysfunction: role of calcium-activated potassium channels.
Desai, KM; Sankaralingam, S; Wilson, TW, 2006
)
3.22
"Clofibrate (Atromid-S) has been found to inhibit the contractility of isolated rabbit aortic muscle rings produced by exposure to either norepinephrine, histamine or angiotensin. "( Clofibrate and vascular smooth muscle: actions on rabbit aorta preparations.
Fairhurst, AS; Kent, G; Purdy, RE, 1981
)
3.15
"Clofibrate has been considered to be a relatively safe antidiuretic in the treatment of diabetes insipidus. "( Clofibrate-induced myopathy in patients with diabetes insipidus.
Chihara, K; Fujita, T; Matsukura, S; Matsumoto, J; Yoshimoto, Y, 1980
)
3.15
"Clofibrate (CFB) has been proposed to increase elimination of bilirubin in neonates with hyperbilirubinemia. "( [Pharmacokinetics of clofibrate in jaundiced newborn infants at term].
Bourget, P; Broise, I; Gabilan, JC; Quinquis-Desmaris, V, 1995
)
2.05
"Clofibrate has cholesterol- and triglyceride-lowering effect. "( [Clofibrate treatment of hyperlipoproteinemia].
Midorikawa, H; Oikawa, S, 1994
)
2.64
"Clofibrate has been reported to prevent the development of hypertension in Dahl S rats, but its mechanism of action remains to be determined. "( Induction of P4504A activity improves pressure-natriuresis in Dahl S rats.
Alonso-Galicia, M; Frohlich, B; Roman, RJ, 1998
)
1.74
"Clofibrate has tumor-promoting and carcinogenic activities, whereas PFDA does not."( Formation of 8-oxodeoxyguanosine in liver DNA and hepatic injury by peroxisome proliferator clofibrate and perfluorodecanoic acid in rats.
Hong, JT; Jang, SJ; Kang, WS; Kim, SC; Yoo, HS; Yun, YP, 1998
)
1.24
"Clofibrate has particular dangers in patients with uraemia or hypoproteinaemia, and we recommend that it be used with great caution in patients with renal disease."( Clofibrate-induced complications in renal disease: a case report.
Gregory, MC; Pokroy, N; Ress, S, 1977
)
2.42

Actions

Clofibrate prevented the increase in SBP produced by salt administration, reduced the sodium balance, and further reduced plasma and tissue thyroid hormone levels. It did not increase the incidence or multiplicity of papillomas, or any other tumors in FVB mice.

ExcerptReferenceRelevance
"Clofibrate did not increase the frequency of MNed cells in the bone marrow in the 14-day study, whereas a slight increase was observed at the highest dose in the 28-day study."( Repeated dose liver micronucleus assay using clofibrate in young adult rats.
Fujii, W; Hori, H; Kawasako, K; Takashima, R; Takayanagi, T; Tanaka, Y; Wako, Y, 2015
)
1.4
"Clofibrate prevented the increase in SBP produced by salt administration, reduced the sodium balance, and further reduced plasma and tissue thyroid hormone levels."( Effects of clofibrate on salt loading-induced hypertension in rats.
Cruz, A; Moreno, JM; Osuna, A; Pérez-Abud, R; Quesada, A; Rodríguez-Gómez, I; Vargas, MÁ; Wangensteen, R, 2011
)
1.48
"Clofibrate was able to increase the expressions of both PPARα and β, but was not able to for PPARγ."( Identification, organ expression and ligand-dependent expression levels of peroxisome proliferator activated receptors in grass carp (Ctenopharyngodon idella).
He, S; Huang, W; Liang, XF; Mai, KS; Qu, CM; Shen, D; Zhang, WB, 2012
)
1.1
"Clofibrate may increase the content of dolichol by enhancing dolichol synthesis from mevalonate."( Effects of peroxisome proliferators gemfibrozil and clofibrate on syntheses of dolichol and cholesterol in rat liver.
Hashimoto, F; Hayashi, H; Ikeda, M; Shiota, Y, 2003
)
1.29
"Clofibrate did not increase the incidence or multiplicity of papillomas, or any other tumors in FVB mice."( Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.
Allen, JS; Campbell, JA; Hoivik, DJ; Jayo, MJ; Kwanyuen, P; Miller, RT; Santostefano, MJ; Selinger, K; Torrey, CE; Wall, HG,
)
1.11
"Clofibrate caused an increase in liver weight without affecting body weight."( Alterations in rat serum lipids and apolipoproteins following clofibrate treatment.
Dashti, N; Ontko, JA, 1983
)
1.23
"A clofibrate-dependent increase in phospholipid synthesis may restrict the amount of exogenous fatty acid which is available for the formation of triglyceride-rich lipoproteins."( Effect of clofibrate on the metabolism of oleate in the perfused rat liver.
Ide, T; Sugano, M, 1983
)
1.23
"Clofibrate produced an increase in the number of peroxisomes and also enhanced the activity of aconitase and histidine: glyoxylate aminotransferase (HGA) in liver homogenate."( [Effect of clofibrate on intracellular enzyme distribution in the rat liver].
Antonenkov, VD; Panchenko, LF; Pirozhkov, SV; Popova, SV, 1983
)
1.38
"Clofibrate is known to increase cholesterol saturation of bile and the prevalence of gallstones. "( Gemfibrozil--the effect of biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate.
Hall, MJ; Howard, AN; Nelson, LM; Russell, RI, 1981
)
1.92
"Clofibrate at lower concentrations (10-200 microM) produced increases in the mRNA levels of cPLA(2) in a dose-response manner."( Modulation of cytosolic phospholipase A(2) by PPAR activators in human preadipocytes.
Choy, PC; Dembinski, T; Hatch, GM; Jiang, YJ; Kroeger, EA; Mymin, D, 2001
)
1.03
"The clofibrate-induced increase in acetyl group production was attributable to enhanced rates of ketone body and acetylcarnitine formation."( Effect of clofibrate treatment on acylcarnitine oxidation in isolated rat liver mitochondria.
Kähönen, M, 1979
)
1.14
"Only clofibrate was found to lower liver cholesterol content after pretreatment for 4 or 18 days."( Comparison of hypocholesterolemic activity for cyclic analogs of clofibrate in normolipemic rats.
Feller, DR; Goldberg, AP; Mellon, WS; Witiak, DT, 1977
)
0.95

Treatment

Clofibrate-treated cells incorporated a 2- or more-fold label from leucine, tyrosine, and bicarbonate into the fatty acid moieties of the lipids than did control cells. In clofibrates-treated rats, serum free cholesterol concentrations increased concurrent with a reduction in serum lecithin: cholesterol acyltransferase activity.

ExcerptReferenceRelevance
"Clofibrate treatment reduced SBP by 26%±2% and proteinuria by 43%±9% in SHR but not in WKY rats."( PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats.
Newaz, M; Yousefipour, Z, 2014
)
1.49
"Clofibrate treatment had no effect on peroxisome proliferator-activated receptor alpha and CPT I mRNA expression."( Effects of lipid-lowering pharmaceutical clofibrate on lipid and lipoprotein metabolism of grass carp (Ctenopharyngodon idellal Val.) fed with the high non-protein energy diets.
Fang, L; Guo, X; He, S; Liang, XF; Shen, D; Yuan, X; Zhou, Y, 2015
)
1.4
"Clofibrate treatment significantly induced PPARα DNA binding activity, and remarkably reduced cyclooxygenase-2/PGE2 and 5-lipoxygenase/LTB4 inflammatory pathways."( Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer.
Chandran, K; Goswami, S; Sharma-Walia, N, 2016
)
1.38
"Clofibrate treatment was shown to concomitantly decrease the liver levels of HNF1α, HNF4α and PCSK9 mRNA, as well as serum PCSK9, TAGs and total cholesterol concentrations in CRF rats."( Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
Rutkowski, B; Sucajtys-Szulc, E; Swierczynski, J; Szolkiewicz, M, 2016
)
1.16
"Clofibrate treatment prevented MI-induced changes in iNOS, MMP-2 and MMP-9, ICAM-1, IL-6, NF-κB, and IκB."( Peroxisome proliferator-activated receptors (PPAR) downregulate the expression of pro-inflammatory molecules in an experimental model of myocardial infarction.
Cervantes-Pérez, LG; Del Valle-Mondragón, L; Ibarra-Lara, Mde L; Oidor-Chan, VH; Pastelín-Hernández, G; Pérez-Severiano, F; Ramírez-Ortega, Mdel C; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria, E; Torres-Narváez, JC, 2016
)
1.16
"Clofibrate treatment significantly upregulated renal HMGCS2 expressions, inhibited phosphorylation of Akt, and decreased malondialdehyde levels and catalase activities in SHRSP kidney tissues (P < 0.05)."( Mitochondrial HMG-CoA synthase partially contributes to antioxidant protection in the kidney of stroke-prone spontaneously hypertensive rats.
Aso, H; Fan, Z; Fu, P; Liu, J; Meng, Y; Nara, Y; Tian, C; Yamori, Y; Yi, W; Ying, C,
)
0.85
"The clofibrate treatment attenuated kidney damage and hepatic oxidative stress while maintaining serum/hepatic sulfatide levels and hepatic CST content in the mice."( Attenuation of kidney injuries maintains serum sulfatide levels dependent on hepatic synthetic ability: a possible involvement of oxidative stress.
Aoyama, T; Hara, A; Kamijo, Y; Kyogashima, M; Nakajima, T; Sheng, X; Sugiyama, E; Takahashi, K; Tanaka, N; Wang, L; Zhang, X, 2012
)
0.86
"Clofibrate treatment stimulated de novo CL biosynthesis via an increase in phosphatidylglycerolphosphate (PGP) synthase activity, accounting for the unaltered CL content."( Stimulation of cardiac cardiolipin biosynthesis by PPARalpha activation.
Choy, PC; Gartshore, J; Gonzalez, FJ; Halayko, AJ; Hatch, GM; Jiang, YJ; Lu, B; Takasaki, J; Taylor, WA; Xu, FY, 2004
)
1.04
"Clofibrate treatment did not statistically affect growth rate."( Effect of dexamethasone, 2-bromopalmitate and clofibrate on L-FABP mediated hepatoma proliferation.
Burczynski, FJ; Rajaraman, G, 2004
)
1.3
"Clofibrate treatment (250 mg/kg/day) of female rasH2 mice was associated with a slight increase in the incidence of various neoplasms (harderian gland, lungs, skin, spleen, tail, thymus, and uterus) compared with untreated transgenic mice and with similarly treated nontransgenic mice."( Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.
Allen, JS; Clarke, CJ; Hoivik, DJ; Miller, RT; Nesfield, SR; Santostefano, MJ; Selinger, K,
)
1.11
"Clofibrate-treated rats were prepared by oral administration of clofibrate 5 h before sacrifice."( Clofibrate treatment promotes branched-chain amino acid catabolism and decreases the phosphorylation state of mTOR, eIF4E-BP1, and S6K1 in rat liver.
Bajotto, G; Goto, H; Hayashi, K; Honda, T; Ishigami, M; Ishiguro, H; Katano, Y; Maeda, K; Nakano, I; Shimomura, Y, 2006
)
2.5
"Clofibrate treatment, however, resulted in a significant decrease in both parameters (p<0.05)."( Role of cytosolic liver fatty acid binding protein in hepatocellular oxidative stress: effect of dexamethasone and clofibrate treatment.
Burczynski, FJ; Gong, Y; Jiang, P; Rajaraman, G; Wang, GQ; Yan, J, 2007
)
1.27
"Clofibrate treatment elevated the levels of N-methylnicotinamide and 3,4-dihydroxymandelate and decreased the levels of 2-oxoglutarate and N-acetylaspartate."( A metabonomics study of the hepatotoxicants galactosamine, methylene dianiline and clofibrate in rats.
Aoki, T; Ishihara, K; Katsutani, N, 2006
)
1.28
"Clofibrate treatment restored protein level and improved hepatic function."( Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats.
Burczynski, F; Gong, Y; Jiang, P; Rajaraman, G; Roberts, MS; Shen, H; Wang, G, 2007
)
1.06
"Clofibrate treated pigs also had higher hepatic mRNA concentrations of bax and the proto-oncogenes c-myc and c-jun and a lower mRNA concentration of bcl-XL than control pigs (P < 0.05)."( Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.
Eder, K; Giemsa, B; Hause, G; Kluge, H; Luci, S, 2007
)
2.5
"All clofibrate pretreated steatohepatitic mice receiving APAP exhibited lower liver injury, which did not progress and the mice survived."( Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate.
Bhave, VS; Donthamsetty, S; Latendresse, JR; Mehendale, HM; Mitra, MS, 2008
)
1.03
"Clofibrate-treated animals did not show a decreased concentration of cytochrome c in hepatic mitochondria."( Influence of starvation and clofibrate administration on oxidative phosphorylation by rat liver mitochondria.
Chhabra, S; Kurup, CK; Rasheed, BK, 1980
)
1.28
"In clofibrate-treated group, the concentration of bile acids and cholesterol in bile was decreased and output of biliary phospholipids was increased."( Effects of N-(4-methylbenzylthiocarbonyl)-L-phenylalanine (KF 1492), a new hypolipidemic drug, and clofibrate on lipids metabolism.
Deguchi, T; Ishii, A; Marumo, H; Tanaka, M, 1983
)
1
"Clofibrate treatment in vivo (of which clofibric acid is the ester hydrolysis product) had no effect on clofibric acid glucuronidation in vitro."( Hepatic microsomal glucuronidation of clofibric acid in the adult and neonate albino rat.
Odum, J; Orton, TC, 1983
)
0.99
"Clofibrate treatment of rats for 2 weeks resulted in a significant decrease in total thyroxine and triiodothyronine levels in serum."( Influence of clofibrate on thyroid hormone and muscle protein turnover.
Adibi, SA; Lehotay, DC; Levey, GS; Paul, HS, 1984
)
1.36
"In clofibrate-treated rats, Lineweaver-Burk plots showed a reduced Vmax for both the BSP and GSH substrates."( Impairment of hepatic glutathione S-transferase activity as a cause of reduced biliary sulfobromophthalein excretion in clofibrate-treated rats.
Celier, C; Foliot, A; Touchard, D, 1984
)
0.99
"Clofibrate treatment increased (p less than 0.01) the combination of very low and low density lipoprotein cholesterol (VLDL + LDL-C) by 42% at the 0.1% dose and lowered HDL-C by 28% at the 0.25% dose; total-C was not changed from control values."( Comparison of clofibrate and ethyl-5-(p-chlorophenoxy)-3-hydroxy-3-methylpentanoate induced changes in serum lipoprotein cholesterol and hepatic peroxisome proliferation in the normal rat.
Block, EM; Day, CE; Stafford, WW; Stevens, TJ, 1983
)
1.35
"Clofibrate-treated cells incorporated a 2- or more-fold label from leucine, tyrosine, and bicarbonate into the fatty acid moieties of the lipids than did control cells, but only slightly more into the glycerol moiety."( Effect of clofibrate on CO2 fixation into glycogen and fatty acids via the leucine catabolism pathway in Tetrahymena.
Blum, JJ, 1980
)
1.38
"In clofibrate-treated rats, serum free cholesterol concentrations increased concurrent with a reduction in serum lecithin: cholesterol acyltransferase activity, but no such correlation was observed for II."( Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: II. High sucrose-fed animals.
Feller, DR; Kokrady, SS; Lanese, RR; Mukhopadhyay, A; Newman, HA; O'Brien, M; Patel, ST; Rice, JC; Witiak, DT, 1983
)
1.08
"Clofibrate treatment decreased drastically the activity of serum postheparin lipoprotein lipase of rats fed with fat-free test diet but had no effect on hepatic lipase. "( Clofibrate decreases jejunal cholesterol synthesis and activity of postheparin plasma lipoprotein lipase in the rat.
Kuusi, T; Miettinen, TA; Strandberg, TE; Tilvis, RS, 1983
)
3.15
"Clofibrate treatment resulted also in an increased activity of the hepatic hexose monophosphate shunt dehydrogenases but was without effect on NADP-linked isocitrate dehydrogenase."( The effect of clofibrate feeding on the NADP-linked dehydrogenases activity in rat tissue.
Swierczyński, J; Zelewski, M, 1983
)
1.35
"Clofibrate treatment did not affect serum lipid levels significantly in either normal or cholesterol-fed mice."( Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
Abiko, Y; Nakayasu, T; Tawara, K; Tomikawa, M, 1981
)
0.98
"Clofibrate treatment coincided with increasing amounts of monounsaturated fatty acids, especially oleate (18 : 1), in the cholesterol esters, triglycerides and phospholipids while there were significant reductions of the content of linoleic (18 : 2) acid in both the cholesterol esters and triglycerides."( Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.
Boberg, J; Gustafsson, IB; Lithell, H; Vessby, B, 1980
)
1.2
"Clofibrate treatment also resulted in a shorter duration of jaundice and a restricted use of phototherapy."( [Clofibrate for the treatment of hyperbilirubinemia in neonates born at term: a double blind controlled study (author's transl)].
Benattar, C; Dehan, M; Foliot, A; Gabilan, JC; Hernandorena, X; Janaud, JC; Leluc, R; Lindenbaum, A; Vial, M, 1981
)
1.89
"Clofibrate treatment appears to result in an increased synthesis of the majority of mitochondrial protein."( Perturbation by clofibrate of mitochondrial levels in animal cells. Implications for a model of mitochondrial genesis.
Lipsky, NG; Pedersen, PL, 1982
)
1.33
"Clofibrate treatment did not affect the frequency of tumors of the large and small intestine but was followed by a significant decrease in the number of large- and medium-size tumors."( Effects of misclerone (clofibrate) on dimethylhydrazine-induced intestinal carcinogenesis in rats.
Berstein, LM; Dilman, VM; Pozharisski, KM, 1982
)
1.3
"Clofibrate-treated mice showed a significant decrease in plasma triacylglycerols and a parallel elevation of liver catalase. "( The effects of clofibrate and 3-amino-1,2,4-triazole on liver catalase and lipid metabolism in mice.
Jones, GL; Neill, AR, 1982
)
2.06
"Clofibrate treatment was associated with decreases in 11.0% in plasma cholesterol."( Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
Crow, LO; Hunninghake, DB; Isaacson, SO; Probstfield, JL, 1981
)
1.29
"On Clofibrate treatment the enzyme activities were 2-3 times higher, but on treatment with CH-123, they were only 1.2-1.8 times above the control."( Effect of CH-1243, a pyrido (1,2-a) pyrimidine derivative on the elevated activity of lysosomal enzymes of rabbit aorta and liver in experimental atherosclerosis.
Ecsedi, GG; Hidvégi, EJ; Virág, S, 1981
)
0.78
"Clofibrate treatment stimulated the net consumption of pyruvate, and inhibited the net production of alanine."( Branched chain amino acid oxidation in cultured rat skeletal muscle cells. Selective inhibition by clofibric acid.
Casanello-Ertl, D; Duducgian-Vartavarian, L; Pardridge, WM, 1980
)
0.98
"Clofibrate treatment resulted in a reduction of plasma cholesterol, hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities."( Effect of probucol on cholesterol metabolism in the rat.
Holets, RJ; Kottke, BA; Li, JR, 1980
)
0.98
"Clofibrate treatment caused an increase in the concentrations of phospholipids and unsaturated long-chain fatty acids and a decrease in the concentrations of triglycerides, free fatty acids, cholesterol and shorter saturated fatty acids."( Lipid composition of liver peroxisomes isolated from untreated and clofibrate-treated mice and rats.
Kyrklund, T; Meijer, J, 1994
)
1.25
"Clofibrate treatment did not influence the activity of NADP-linked isocitrate dehydrogenase and malate dehydrogenase (enzymes not linked directly to lipogenesis), either in BAT, liver or WAT."( Inhibition of lipogenesis in rat brown adipose tissue by clofibrate.
Bukato, G; Kochan, Z; Swierczynski, J, 1993
)
1.25
"Clofibrate treatment resulted in a lighter LDL subfraction pattern (LDL1-LDL4)."( Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment.
de Graaf, J; Demacker, PN; Hendriks, JC; Stalenhoef, AF, 1993
)
1.2
"In clofibrate-treated SS/Jr rats (n = 12), the omega-hydroxylation of arachidonic and lauric acids by renal cortical and outer medullary microsomes was greater than that seen in vehicle-treated rats (n = 9).(ABSTRACT TRUNCATED AT 250 WORDS)"( Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats.
Frohlich, B; Ma, YH; Markham, B; Roman, RJ, 1993
)
2.24
"Clofibrate treatment had no significant effects on testosterone 7 alpha-hydroxylase (T7 alpha OH), 7-ethoxyresorufin O-deethylase (EROD), or benzphetamine N-demethylase (BZDM) activities."( Distinct responses of mouse hepatic CYP enzymes to corn oil and peroxisome proliferators.
Juvonen, R; Kojo, A; Pasanen, M; Pelkonen, O; Pellinen, P; Raunio, H, 1996
)
1.02
"Clofibrate treatment for 2 weeks resulted in (a) a 3-fold increase in the flux through BCKDH in mitochondria isolated from rat liver, and (b) a modest but significant increase in the activity of BCKDH."( Alteration in gene expression of branched-chain keto acid dehydrogenase kinase but not in gene expression of its substrate in the liver of clofibrate-treated rats.
Adibi, SA; Liu, WQ; Paul, HS, 1996
)
1.22
"Clofibrate pretreatment of the animals resulted in a strong induction of omega-oxidation, with a decrease in the ability to catalyze epoxidation of internal olefins, whereas phenobarbital pretreatment only stimulated (omega-1)-hydroxylation without any effect on epoxidation."( In vitro hydroxylation and epoxidation of some isomeric lauric acid analogs by rat liver microsomes. Identification of metabolites and effects of clofibrate or phenobarbital pretreatment.
Boucher, JL; Delaforge, M; Durst, F; Mioskowski, C; Pflieger, P; Pinot, F; Salaün, JP, 1996
)
1.22
"Clofibrate-treated female rat liver supernatants had higher LDH levels and produced more oxalate from glyoxylate."( Clofibrate feeding to Sprague-Dawley rats increases endogenous biosynthesis of oxalate and causes hyperoxaluria.
Schwille, PO; Sharma, V, 1997
)
2.46
"Clofibrate treatment resulted in an approximately 100% increase (p < 0.01) in both male and female marmoset cyanide-insensitive palmitoyl CoA oxidase activity and a similar increase (p < 0.05) in male (only) lauric acid 11-hydroxylase activity."( Effects of di-isononyl phthalate (DINP) on peroxisomal markers in the marmoset-DINP is not a peroxisome proliferator.
Hall, M; Harling, R; Matthews, A; Webley, L, 1999
)
1.02
"Clofibrate-treated rats showed typical changes with increases in hepatic PCoA oxidase and CAT activity (5.8-fold and 22.8-fold) and in total CYP (1.66-fold) compared with control."( Investigation of the potential of conjugated linoleic acid (Cla) to cause peroxisome proliferation in rats.
Jones, PA; Lea, LJ; Pendlington, RU, 1999
)
1.02
"Clofibrate treatment increased cytosolic concentrations of L-FABP 4.2+/-0.8-fold, the rate of cytoplasmic diffusion of palmitate 4.3+/-1.7-fold, and the steady-state palmitate extraction 1.5+/-0.3-fold (mean+/-S.E.)."( Induction of hepatic cytosolic fatty acid binding protein with clofibrate accelerates both membrane and cytoplasmic transport of palmitate.
Luxon, BA; Milliano, MT; Weisiger, RA, 2000
)
1.27
"Clofibrate treatment caused the reduction of hepatic CYP4F16 expression and this effect was not dependent on PPARalpha."( Molecular cloning and regulation of expression of two novel mouse CYP4F genes: expression in peroxisome proliferator-activated receptor alpha-deficient mice upon lipopolysaccharide and clofibrate challenges.
Barclay, TB; Cui, X; Gonzalez, FJ; Kawashima, H; Morgan, ET; Peters, JM; Strobel, HW, 2001
)
1.22
"Clofibrate is the treatment of choice in exudative diabetic retinopathy. "( [Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years (author's transl)].
Dorne, PA, 1977
)
1.96
"In clofibrate-treated rats, the tumor cells showed a slight increase in the size of microbodies and in catalase activity; however, the tumor microbodies did not increase in number."( Response of microbodies in Morris hepatoma 9618A to clofibrate.
Gotoh, M; Itabashi, M; Mochizuki, Y; Morris, HP; Tsukada, H, 1975
)
1.02
"With clofibrate treatment, plasma triglyceride (194 +/- 11 to 157 +/- 10 mg/100 ml; P less than .01) and cholesterol (242 +/- 8 to 212 +/- 8 mg/100 ml; P less than .002) concentrations both decreased significantly despite the continued administration of stable immunosuppressive doses of prednisolone."( Effects of clofibrate on plasma lipids and high-density lipoprotein levels in renal allograft recipients.
Albers, JJ; Bagdade, JD; Shantharam, VV; Sollek, M, 1979
)
1.1
"Clofibrate treatment significantly lowered fasting blood glucose levels (p less than 0.01) and improved the glucose tolerance (p less than 0.01)."( The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.
Enger, SC; Johnsen, V; Laws, EA; Samuelsen, A, 1977
)
1.34
"Clofibrate treatment increased mitochondrial and peroxisomal oxidation 2- and 6- to 8-fold, respectively."( Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats.
De Schepper, PJ; Debeer, LJ; Mannaerts, GP; Thomas, J, 1979
)
1.19
"Clofibrate treatment also induced an increase of many times in the activities of mitochondrial alpha-GPD and carnitine acyltransferases, the effect increasing with the dose used."( Effect of clofibrate and gemfibrozil on the activities of mitochondrial carnitine acyltransferases in rat liver. Dose--response relations.
Kähönen, MT; Ylikahri, RH, 1979
)
1.38
"Clofibrate treatment resulted in significant increases in the volumes of the hepatocytes and their constituent mitochondria and microbodies and caused a proliferation of the smooth-surfaced endoplasmic reticulum."( A quantitative analysis of fine structure and drug metabolism in livers of clofibrate-treated young adult and retired breeder rats.
Anthony, LE; Jones, AL; Mooney, JS; Schmucker, DL, 1978
)
1.21
"Clofibrate treatment did not affect blood pH or bicarbonate levels."( Renal gluconeogenesis in clofibrate-treated rats.
Haettinger, JR; Mackerer, CR, 1978
)
1.28
"Clofibrate-treated breeders manifested reduction in blood pressure and in the incidence and severity of arterial disease characteristic of repeatedly-bred rats."( Clofibrate retardation of naturally-occurring arteriosclerosis in repeatedly-bred male and female rats.
Greenberg, BP; Wexler, BC, 1978
)
2.42
"Clofibrate-treated animals had higher serum corticosterone levels than those given isoproterenol alone."( Protective effects of clofibrate on isoproterenol-induced myocardial infarction in arteriosclerotic and non-arteriosclerotic rats.
Greenberg, BP; Wexler, BC, 1978
)
1.29
"Clofibrate treatment was ineffective."( [Arhinencephaly detected by a pitressin-sensitive diabetes insipidus].
Broyer, M; Czernichow, P; Guesry, P; Palcoux, JB, 1978
)
0.98
"Clofibrate treatment resulted in a significant rise of low density lipoprotein cholesterol."( A two-year crossover therapeutic trial with halofenate and clofibrate.
Azarnoff, DL; Dujovne, CA; Hassanein, K; Hurwitz, A; Manion, C; Pentikainen, P,
)
1.1
"Clofibrate treatment induces a triglyceride reduction (incrementTG) which is correlated with the reduction in the insulin/glucagon molar ration (incrementI/G)."( Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment.
Assan, R; Crepaldi, G; Fedele, D; Muggeo, M; Tiengo, A, 1975
)
1.2
"Clofibrate treatment increased the total activity of carnitine acetyltransferase over 30 times, whereas the total activities of the other two transferases were increased only 5-fold."( Effect of clofibrate treatment on carnitine acyltransferases in different subcellular fractions of rat liver.
Kahonen, MT, 1976
)
1.38
"Clofibrate-treatment increases hepatic CoA content and carnitine acetyltransferase activity, both of which may modulate propionate toxicity."( Interaction of carnitine and propionate with pyruvate oxidation by hepatocytes from clofibrate-treated rats: importance of coenzyme A availability.
Brass, EP, 1992
)
1.23
"Clofibrate treatment improved TG metabolism and the histological and clinical findings in the psoriatic lesion."( [Clofibrate treatment of psoriasis with hypertriglycemia--clinical, histological and laboratory analysis].
Asagami, C; Imamura, T; Matsutani, Y; Ogasawara, M; Takata, I; Yamamoto, T, 1991
)
1.91
"Clofibrate treatment enhanced the rates of PGE2, PGF2, and PGD2 degradation by 85%, 278% and 137%, respectively."( Effect of clofibrate treatment on hepatic prostaglandin catabolism and action.
Brass, EP; Ruff, LJ, 1991
)
1.41
"In clofibrate-treated rats, mRNA activity for acyl-CoA oxidase (AO), the rate-limiting enzyme of the peroxisomal beta-oxidation system, was increased markedly compared with the control, whereas the increase was less than 2-fold in PHMO-treated rats."( Different regulation of hepatic peroxisomal beta-oxidation activity in rats treated with clofibrate and partially hydrogenated marine oil.
Horie, S; Suga, T, 1990
)
1.01
"Clofibrate treatment was found to increase by a factor of two the activity of malonyl-CoA-dependent palmitic acid chain elongation in crude 'microsomal' fractions isolated from rat small intestine. "( Chain elongation of fatty acids in rat small intestine: subcellular localization and effects of clofibrate and partially hydrogenated fish oil.
Christiansen, EN; Nilsson, A; Prydz, K; Rørtveit, T; Thomassen, MS, 1990
)
1.94
"Clofibrate treatment caused a doubling in number and average size of peroxisomes."( Effects of clofibrate treatment and of starvation on peroxisomes, mitochondria, and lipid droplets in mouse hepatocytes: a morphometric study.
Afzelius, BA; Meijer, J, 1989
)
1.39
"Clofibrate-treated rats, in contrast, displayed a panacinar increase in liver fatty acid binding protein with maintenance of the portal-to-central ratio observed in untreated males."( Acinar heterogeneity of fatty acid binding protein expression in the livers of male, female and clofibrate-treated rats.
Barker, ME; Bass, NM; Jones, AL; Manning, JA; Ockner, RK, 1989
)
1.22
"Clofibrate treatment was found to increase total protein synthesis, synthesis of soluble epoxide hydrolase and translational efficiency of the isolated polyribosomes."( In vitro translation of cytosolic and peroxisomal epoxide hydrolase and catalase on liver polyribosomes from untreated and clofibrate-treated C57B1/6 mice.
Joste, V; Meijer, J, 1989
)
1.21
"Clofibrate treatment significantly increased liver weight; as a result glutathione S-transferase activity (toward 1-chloro-2,4-dinitrobenzene) fell if expressed per gram of liver (4560 +/- 420 (SE) vs 7010 +/- 260 nmoles/min for clofibrate treated and controls respectively, p less than 0.002), but was unchanged when expressed per total liver (60.8 +/- 6.5 vs 64.6 +/- 3.5 mumoles/min for clofibrate and controls p greater than 0.5)."( The hepatocellular transport of sulfobromophthalein-glutathione by clofibrate treated, perfused rat liver.
Bass, NM; Licko, V; Sorrentino, D; Weisiger, RA, 1989
)
1.23
"Clofibrate treatment resulted in an enhancement of peroxisomal beta-oxidizing capacity in various tissues."( Peroxisomal and mitochondrial beta-oxidation of monocarboxylyl-CoA, omega-hydroxymonocarboxylyl-CoA and dicarboxylyl-CoA esters in tissues from untreated and clofibrate-treated rats.
Draye, JP; Vamecq, J, 1989
)
1.2
"Clofibrate treatment (30 mg/100 g rat/day for 2 wk) increased significantly the concentration (nmol/g, mean +/- SE, 6 rats) of both free (289 +/- 21 vs."( Mechanism of increased hepatic concentration of carnitine by clofibrate.
Adibi, SA; Gleditsch, CE; Paul, HS, 1986
)
1.23
"4- Clofibrate treatment of the rats resulted in a six fold increase in microsomal cytochrome P-450 clo as judged by immunochemical quantification."( Purification and characterization of a cytochrome P-450 isozyme isolated from the liver of rats pretreated with clofibrate.
Célier, C; Kiffel, L; Leroux, JP, 1988
)
1
"Clofibrate treatment of mice decreased the labeling density of epoxide hydrolase and catalase in hepatocytes peroxisomes, as expected, and more unlabeled peroxisomes were observed."( Immunocytochemical analysis of soluble epoxide hydrolase and catalase in mouse and rat hepatocytes demonstrates a peroxisomal localization before and after clofibrate treatment.
Hollinshead, M; Meijer, J, 1988
)
1.19
"Clofibrate or DEHP treatment induced both cytosolic and microsomal epoxide hydrolases in nearly all of the strains examined."( Hepatic epoxide hydrolase activities and their induction by clofibrate and diethylhexylphthalate in various strains of mice.
Gill, SS; Kaur, S, 1987
)
1.24
"Clofibrate treatment significantly reduced the content of esterified cholesterol in this vessel."( Influence of clofibrate on the plasma lipoprotein pattern and on the lipid content and protein and collagen synthesis in atherosclerotic coronary arteries and abdominal aorta from hypercholesterolemic mini-pigs.
Jacobsson, L, 1987
)
1.36
"Clofibrate treatment was shown to increase the content of reduced glutathione in rat liver and kidney, but did not alter the glutathione level in heart, brain, spleen and small intestine. "( Effect of clofibrate treatment on glutathione content and the activity of the enzymes related to peroxide metabolism in rat liver and heart.
Antonenkov, VD; Gusev, VA; Panchenko, LF, 1987
)
2.12
"In clofibrate-treated rats, the value reached about 85%."( Participation of peroxisomes in the metabolism of xenobiotic acyl compounds: comparison between peroxisomal and mitochondrial beta-oxidation of omega-phenyl fatty acids in rat liver.
Horie, S; Ogawa, S; Suga, T; Watanabe, T; Yamada, J, 1987
)
0.79
"Clofibrate treatment had different effects on the oleate-binding capacity of cytosolic proteins: an increase in liver and kidney, no change in skeletal muscle and a decrease in heart."( Fatty acid-binding capacity of cytosolic proteins of various rat tissues: effect of postnatal development, starvation, sex, clofibrate feeding and light cycle.
Jansen, GP; Paulussen, RJ; Veerkamp, JH, 1986
)
1.2
"Clofibrate treatment increased mRNA activity for thiolase approx."( Synthesis of 3-ketoacyl-CoA thiolase of rat liver peroxisomes on free polyribosomes as a larger precursor. Induction of thiolase mRNA activity by clofibrate.
Fujiki, Y; Lazarow, PB; Mortensen, RM; Rachubinski, RA, 1985
)
1.19
"Clofibrate treatment caused a 1.5 to 2.3-fold increase in the liver specific aldehyde dehydrogenase activity."( Intraparticulate localization and some properties of a clofibrate-induced peroxisomal aldehyde dehydrogenase from rat liver.
Antonenkov, VD; Panchenko, LF; Pirozhkov, SV, 1985
)
1.24
"Clofibrate-treatment of rats decreased the actual activity and activity state of the branched-chain 2-oxo acid dehydrogenase complex in quadriceps muscle, and increased the total activity in heart and liver without a change of the activity state."( Effect of clofibrate on branched-chain amino acid metabolism.
Schepens, JT; van Moerkerk, HT; Veerkamp, JH; Wagenmakers, AJ, 1985
)
1.39
"Clofibrate treatment shifted the apparent subcellular compartmentation of all three enzymatic activities with an increase in the ratio of soluble to particulate activity."( Epoxide metabolism in the liver of mice treated with clofibrate (ethyl-alpha-(p-chlorophenoxyisobutyrate)), a peroxisome proliferator.
Hammock, BD; Loury, DN; Moody, DE, 1985
)
1.24
"Clofibrate treatment of mice was found to increase liver cytosolic epoxide hydrolase concentration by two fold, showing that the increase in cytosolic epoxide hydrolase in mouse liver after clofibrate treatment is primarily due to induction."( The regulation of cytosolic epoxide hydrolase in mice.
Gill, SS; Pichare, MM, 1985
)
0.99
"Treatment with clofibrate is also associated with a decrease in ANP and ANPr expression."( PPAR Alpha Activation by Clofibrate Alleviates Ischemia/Reperfusion Injury in Metabolic Syndrome Rats by Decreasing Cardiac Inflammation and Remodeling and by Regulating the Atrial Natriuretic Peptide Compensatory Response.
Cano-Martínez, A; Castrejón-Téllez, V; Díaz-Díaz, E; Ibarra-Lara, L; Osorio-Yáñez, C; Pavón, N; Rubio-Ruíz, ME; Sánchez-Aguilar, M; Soria-Castro, E, 2023
)
1.55
"Fish treated with clofibrate exhibited increased hepatic acyl-CoA oxidase activity, but did not show any changes in carnitine palmitoyltransferase (CPT) I activity compared with HC and HF diets without clofibrate."( Effects of lipid-lowering pharmaceutical clofibrate on lipid and lipoprotein metabolism of grass carp (Ctenopharyngodon idellal Val.) fed with the high non-protein energy diets.
Fang, L; Guo, X; He, S; Liang, XF; Shen, D; Yuan, X; Zhou, Y, 2015
)
1.01
"Pretreatment with clofibrate, a peroxisome proliferator-activated receptor alpha (PPARa) agonist, protects mice from acetaminophen (APAP) injury. "( Enhanced hepatotoxicity by acetaminophen in Vanin-1 knockout mice is associated with deficient proliferative and immune responses.
Chasson, L; Ferreira, DW; Galland, F; Goedken, MJ; Manautou, JE; Naquet, P; Rommelaere, S, 2016
)
0.77
"Treatment with clofibrate significantly accelerated normalization of barrier function."( Topical peroxisome proliferator activated receptor activators accelerate postnatal stratum corneum acidification.
Crumrine, D; Elias, PM; Feingold, KR; Fluhr, JW; Hachem, JP; Man, MQ; Mauro, TM, 2009
)
0.69
"Pretreatment with clofibrate increased the chiral inversion of (R)-FPF in favour of the pharmacologically active (S)-FPF enantiomer."( Chiral inversion of (R)-(-)-fenoprofen in guinea-pigs pretreated with clofibrate.
Fogel, F; Islas, S; San Martín, MF; Soraci, A; Tapia, O, 2002
)
0.87
"Treatment with clofibrate, a PPARalpha-activating ligand, led to a marked decrease in fatty liver and complete abrogation of necroinflammatory changes in FE rats."( Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation.
Bass, NM; Dannenberg, AJ; Jokelainen, K; Nanji, AA, 2004
)
0.66
"Treatment with clofibrate significantly increased glomerular CYP450 4A expression."( Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier.
McCarthy, ET; Sharma, M; Sharma, R, 2005
)
0.67
"Treatment with clofibrate also resulted in a shorter duration of jaundice and a decreased use of phototherapy (P < 0.0001)."( Effect of clofibrate in jaundiced term newborns.
Farhat, ASh; Iranpour, R; Mohammadzadeh, A, 2005
)
1.07
"Pretreatment with clofibrate results in partial reversal of changes produced by valproate."( Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes.
Balasubramanian, KA; Eapen, CE; Natarajan, SK; Pullimood, AB, 2006
)
0.66
"Pigs treated with clofibrate had higher hepatic activities of T(3)- and T(4)-UDP glucuronosyltransferases (UGT) and lower concentrations of total and free T(4) and total T(3) in plasma than control pigs (P < 0.05)."( Clofibrate increases hepatic triiodothyronine (T3)- and thyroxine (T4)-glucuronosyltransferase activities and lowers plasma T3 and T4 concentrations in pigs.
Eder, K; Hirche, F; Kluge, H; Luci, S, 2006
)
2.1
"Pigs treated with clofibrate had heavier livers, moderately increased mRNA concentrations of various PPAR-alpha target genes in liver and adipose tissue, a higher concentration of 3-hydroxybutyrate, and markedly lower concentrations of triglycerides and cholesterol in plasma and lipoproteins than control pigs (P < 0.05)."( Clofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs.
Eder, K; Giemsa, B; Kluge, H; Luci, S, 2007
)
2.11
"Pigs treated with clofibrate had heavier livers (+16%), higher peroxisome counts (+61%), higher mRNA concentration of acyl-CoA oxidase (+66%), a higher activity of catalase (+41%) but lower concentrations of hydrogen peroxide (-32%) in the liver than control pigs (P < 0.05); concentrations of lipid peroxidation products (thiobarbituric acid-reactive substances, conjugated dienes) and total and reduced glutathione in the liver did not differ between both groups. "( Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.
Eder, K; Giemsa, B; Hause, G; Kluge, H; Luci, S, 2007
)
2.12
"Hens treated with clofibrate also had lower mRNA concentrations of fatty acid synthase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and low-density lipoprotein receptor, proteins involved in fatty acid biosynthesis and cholesterol biosynthesis and uptake, than hens fed the control diet (P<0.05)."( Effects of clofibrate treatment in laying hens.
Brandsch, C; Eder, K; Haase, K; Kluge, H; König, B; Stangl, GI, 2007
)
1.05
"Pigs treated with clofibrate had higher relative mRNA concentrations of OCTN2 in liver (3.1-fold), skeletal muscle (1.5-fold) and epithelial cells from small intestine (1.8-fold) than control pigs (P<0.05)."( Clofibrate treatment up-regulates novel organic cation transporter (OCTN)-2 in tissues of pigs as a model of non-proliferating species.
Eder, K; Fischer, M; Geissler, S; Hirche, F; Kluge, H; Luci, S; Ringseis, R; Spielmann, J; Wen, G, 2008
)
2.11
"The treatment with clofibrate gave the following results: fall in total serum cholesterol (-25%), increase in liver weight (+89%) and hepatic catalase activity (+69%), high proliferation of hepatic peroxisomes (+246%)."( [Comparative biochemical and ultrastructural study of the hepatic response induced in the rat by 2 hypolipemic agents: clofibrate and itanoxone].
Delhon, A; Fauran, F; Gendre, PM; Lauressergues, H; Marcelon, G,
)
0.66
"Treatment with clofibrate on the cholesterol-fed rats resulted in a decrease in the volume of smooth ER in both cortical zones."( Effects of cholesterol-rich diet and hypolipidemic drug (clofibrate, CPIB) on the adrenal cortex in rats--ultrastructural stereological and biochemical analysis.
Fukunishi, R; Matsumoto, K; Mori, H; Takeuchi, N, 1981
)
0.85
"Treatment with clofibrate and gemfibrozil both resulted in significant reductions in the plasma concentrations of total cholesterol (40% and 54%), VLDL cholesterol (59% and 79%) and total triglycerides (48% and 70%), as well as a significant increase in HDL cholesterol (9% and 7%)."( Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
Illingworth, DR; Larsen, ML; O'Malley, JP, 1994
)
0.9
"The treatment with clofibrate caused the appearance of GST-P-negative foci, increased in size as compared to GST-P-positive foci in the same liver or induced by the DEN alone."( Immunohistochemical demonstration of the gap junctional protein connexin 32 and proliferating cell nuclear antigen in glutathione S-transferase placental form-negative lesions of rat liver induced by diethylnitrosamine and clofibrate.
Ito, S; Tateno, C; Tuda, M; Yoshitake, A,
)
0.63
"The treatment with clofibrate, a mammalian inducer of 4A subfamily, induced both in liver and kidney of pheasant: i) a protein that cross-reacted with anti rat P450 4A1 and ii) the (omega) and (omega-1) lauric acid hydroxylase activities, known to be associated in mammals to this P450 subfamily."( Cytochrome P450-dependent monooxygenase activities and their inducibility by classic P450 inducers in the liver, kidney, and nasal mucosa of male adult ring-necked pheasants.
Amato, G; Gervasi, PG; Giorgi, M; Longo, V; Marini, S; Mazzaccaro, A, 2000
)
0.63
"Treatment with clofibrate increased FABP levels, the fraction of NBD-stearate found in cytosol, and the observed cytoplasmic diffusion rate."( The peroxisomal proliferator clofibrate enhances the hepatic cytoplasmic movement of fatty acids in rats.
Luxon, BA; Milliano, MT, 2001
)
0.94
"Treatment with clofibrate in doses which normalized the plasma free fatty acid/albumin ratio also prevented the tumor-associated rise in plasma fibrinogen."( Suppression of tumor-associated hyperfibrinogenemia and free fatty acidemia with p-phenoxybenzalbutyrate (clofibrate).
Pickart, L; Thaler, MM, 1979
)
0.81
"Pre-treatment with clofibrate caused a definite improvement in survival, less shock and prostration, and ECG evidence of little or no ischemia."( Protective effects of clofibrate on isoproterenol-induced myocardial infarction in arteriosclerotic and non-arteriosclerotic rats.
Greenberg, BP; Wexler, BC, 1978
)
0.89
"Treatment with clofibrate partially prevented the changes in the concentration of these metabolites and resulted in a significant increase in the activity of hepatic alpha-glycerophosphate dehydrogenase."( Effect of clofibrate on cholesterol and lipid metabolism in ethanol - treated mice.
Rawat, AK, 1975
)
1
"Treatment with clofibrate and 2-diethylhexylphthalate (DEHP) increased microsomal and mitochondrial ubiquinone contents, but a decrease was observed in lysosomes."( The effects of inducers of the endoplasmic reticulum, peroxisomes and mitochondria on the amounts and synthesis of ubiquinone in rat liver subcellular membranes.
Appelkvist, EL; Dallner, G; Kalén, A, 1990
)
0.62
"Rats treated with clofibrate revealed foci of cellular alteration that were more often basophilic and occurred slightly sooner (wk 42) than those in untreated controls (wk 60)."( Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: their rate of onset and their reversibility.
Greaves, P; Irisarri, E; Monro, AM, 1986
)
0.82
"Rats treated with clofibrate (0.3%, w/w) showed a significant increased clofibroyl-CoA hydrolase activity where the cytosolic hydrolase was increased 3.5-fold."( Induction of cytosolic clofibroyl-CoA hydrolase activity in liver of rats treated with clofibrate.
Aarsaether, N; Aarsland, A; Berge, RK; Gjellesvik, DR; Osmundsen, H; Stensland, E; Tsegai, G, 1987
)
0.82
"Treatment with clofibrate is known to increase drastically the number of peroxisomes in mammalian liver."( Unsuccessful attempts to induce peroxisomes in two cases of Zellweger disease by treatment with clofibrate.
Björkhem, I; Blomstrand, S; Glaumann, H; Strandvik, B, 1985
)
0.83

Toxicity

Clofibrate protects against the toxic effects of hypoglycin. Some enzyme inhibitions as indicated by dicarboxylic aciduria are only partly prevented. A single dose of 50 mg/kg is effective, safe and cost effective.

ExcerptReferenceRelevance
" A marginally toxic concentration of CPIB [0."( Sensitization of chronic myeloid leukemia cells to adriamycin cytotoxicity by clofibrate.
Advani, S; Chitnis, M; Parekh, H; Satyamoorthy, K, 1990
)
0.51
" It is demonstrated that propylthiouracil-induced hypothyroid-hyperlipidemic chick develops severe toxic manifestations following clofibrate administration."( Propylthiouracil-induced hypothyroid hyperlipidemic chick: a model for clofibrate-induced toxicity.
Cho, C; Linscheer, WG; Raheja, KL, 1986
)
0.71
" Adverse side effects ranging from mere annoyances to uncommon serious consequences may be associated with dietary modification, recreational physical exercise, and drug intervention."( Adverse effects of the treatment for hyperlipidemia.
Malinow, MR, 1986
)
0.27
" It was concluded that although clofibrate protects against the toxic effects of hypoglycin, some enzyme inhibitions as indicated by dicarboxylic aciduria are only partly prevented."( Organic aciduria in rats made resistant to hypoglycin toxicity by pretreatment with clofibrate.
Bartlett, K; Sherratt, HS; Veitch, RK, 1987
)
0.78
" So, the toxicogenomics through this technology may be very powerful for understanding the effect of unknown toxic mechanisms in biological system."( Gene expression analysis of peroxisome proliferators- and phenytoin-induced hepatotoxicity using cDNA microarray.
Hwang, JW; Hwang, SY; Jeon, KS; Jung, JW; Kang, JS; Kang, KS; Kim, YS; Lee, GJ; Lee, WS; Lee, YS; Li, P; Oh, MJ; Park, JE; Park, JS; Song, BS; Um, CH; Yeo, CD; Youn, JP, 2004
)
0.32
" At elevated concentrations, they can also be toxic to isolated beta-cells."( Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity.
Hannaert, JC; Hellemans, K; Kerckhofs, K; Martens, G; Pipeleers, D; Van Veldhoven, P, 2007
)
0.34
" On the 32nd day, a marginally toxic dose of APAP (360 mg/kg, ip) yielded 70% mortality in steatohepatitic mice, while all non steatohepatitic mice receiving the same dose survived."( Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate.
Bhave, VS; Donthamsetty, S; Latendresse, JR; Mehendale, HM; Mitra, MS, 2008
)
0.55
"While glucocorticoids (GC) exert beneficial effects (anti-inflammatory), they also have adverse effects on the epidermis including decreased epidermal differentiation, decreased keratinocyte proliferation, and decreased cutaneous permeability barrier homeostasis."( Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis.
Chang, S; Choi, EH; Demerjian, M; Elias, PM; Feingold, KR; Man, MQ, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"A single dose of 50 mg/kg clofibrate in treatment of neonatal hyperbilirubinemia is effective, safe and cost effective in view of reducing hospital stay days."( Single dose of 50 mg/kg clofibrate in jaundice of healthy term neonates: randomised clinical trial of efficacy and safety.
Fallah, R; Islami, Z; Lotfi, SR, 2012
)
0.99
"These results indicate that mice lacking Vnn1 have deficiencies in compensatory repair and immune responses following toxic APAP exposure and that these mechanisms may contribute to the enhanced hepatotoxicity seen."( Enhanced hepatotoxicity by acetaminophen in Vanin-1 knockout mice is associated with deficient proliferative and immune responses.
Chasson, L; Ferreira, DW; Galland, F; Goedken, MJ; Manautou, JE; Naquet, P; Rommelaere, S, 2016
)
0.43
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43

Pharmacokinetics

Clofibrate is a new lipid-lowering agent with a more pronounced pharmacological effect, a different metabolism and a much shorter apparent half-life. In 6 patients given cholestyramine together with clfibrate, there was no significant alteration in fasting plasma CPIB levels, 24-hour urinary and faecal excretion of CPIB.

ExcerptReferenceRelevance
" The half-life of plasma CPIB was measured over 48 h after a single 1-g dose of clofibrate in patients who had not received this drug for at least 3 weeks."( Pharmacokinetics of clofibrate in familial hypercholesterolemia.
Boulet, L; Davignon, J; Pichardo, R, 1977
)
0.81
" After concomitant single-dose administration, the serum p-chlorophenoxyisobutyric acid levels, bioavailability parameters, and pharmacokinetic parameters investigated provided no evidence for an interaction and suggested that colestipol and clofibrate can be administered concomitantly or at separated in tervals according to whichever dosage regimen is deemed advisable by the physician."( The effect of colestipol hydrochloride on the bioavailability and pharmacokinetics of clofibrate.
Albert, KS; DeSante, KA; DiSanto, AR; Vecchio, TJ; Weber, DJ; Welch, RD,
)
0.54
" No significant differences were seen in the pharmacokinetic parameters observed for antipyrine, a drug which is less than 10% bound to plasms proteins."( Pharmacokinetics of drugs in patients with the nephrotic syndrome.
Azarnoff, DL; Cohlmia, JB; Gugler, R; Huffman, DH; Shoeman, DW, 1975
)
0.25
" In 6 patients given cholestyramine together with clofibrate, there was no significant alteration in fasting plasma CPIB levels, 24-hour urinary and faecal excretion of CPIB or in the half-life and pool size of the drug."( Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man.
Ahrens, EH; Sedaghat, A, 1975
)
0.75
" When plasma FFA were elevated to about 2,000 muEq/1, the CPIB elimination half-life decreased form 19."( Clofibrate pharmacokinetics: effect of elevation of plasma-free fatty acids.
Cenedella, RJ; Crouthamel, WG, 1975
)
1.7
" Application of the assay in a pilot pharmacokinetic study showed significant differences between the kinetics of the two enantiomers."( Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA).
Mayer, S; Mutschler, E; Spahn-Langguth, H, 1991
)
0.28
" The pharmacokinetic and metabolic study of itanoxone and clofibric acid in the crab shows a difference between the two drugs."( Pharmacokinetic and metabolic study of itanoxone in the crab Pachygrapsus marmoratus (Decapoda, Brachyura): comparative study with clofibric acid.
Chanal, JL; Delhon, A; Lautier, J, 1986
)
0.27
" The pharmacokinetic parameters of the metabolites after oral application of 2 capsules Duolip, corresponding to 500 mg etofylline clofibrate, were evaluated in 7 healthy volunteers."( [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic].
Donike, M; Erking, W; Lücker, PW; Wetzelsberger, K, 1980
)
0.72
" A mechanistic scheme for the degradation of plafibride is proposed, which agrees with the observed pharmacological and pharmacokinetic data."( Pharmacokinetic approach of plafibride in rat.
Bruseghini, L; Ribalta, JM; Torres, A; Vilageliu, J; Zapatero, D, 1981
)
0.26
"Bezafibrate is a new lipid-lowering agent with a more pronounced pharmacological effect, a different metabolism and a much shorter apparent half-life than clofibrate."( Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
Kaufmann, B; Ledermann, H, 1981
)
0.46
" Serum concentrations of both CFB and clofibric acid (CFA) were measured by HPLC and the pharmacokinetic analysis was made by a non-compartmental method."( [Pharmacokinetics of clofibrate in jaundiced newborn infants at term].
Bourget, P; Broise, I; Gabilan, JC; Quinquis-Desmaris, V, 1995
)
0.61
" Pharmacokinetic profiles were similar in both groups of infants."( [Pharmacokinetics of clofibrate in jaundiced newborn infants at term].
Bourget, P; Broise, I; Gabilan, JC; Quinquis-Desmaris, V, 1995
)
0.61
" All members of this class are primarily excreted via the kidneys and display some increase in plasma half-life in individuals with severe renal impairment."( Clinical pharmacokinetics of fibric acid derivatives (fibrates).
Miller, DB; Spence, JD, 1998
)
0.3
"Disposition kinetics of [(3)H]palmitate and its low-molecular-weight metabolites in perfused rat livers were studied using the multiple-indicator dilution technique, a selective assay for [(3)H]palmitate and its low-molecular-weight metabolites, and several physiologically based pharmacokinetic models."( Fatty acid binding protein is a major determinant of hepatic pharmacokinetics of palmitate and its metabolites.
Anissimov, YG; Burczynski, FJ; Chang, P; Hung, DY; Lewis, A; Masci, PP; Roberts, MS; Siebert, GA, 2003
)
0.32

Compound-Compound Interactions

There are insufficient data from different countries on the use of clofibrate in combination with phototherapy for hyperbilirubinaemia.

ExcerptReferenceRelevance
" Further studies are required of other well-recognized groups of patients on drugs which are known to interact to assess the relevance and clinical importance of the formidable lists of interactions which are now available to doctors who prescribe drugs."( Drug interactions in patients on long-term oral anticoagulant and antihypertensive adrenergic neuron-blocking drugs.
Petrie, JC; Starr, KJ, 1972
)
0.25
"Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance."( Drug interactions with fibric acids.
Dujovne, CA; Lozada, A, 1994
)
0.29
"To determine the efficacy and safety of clofibrate in combination with phototherapy versus phototherapy alone in unconjugated neonatal hyperbilirubinaemia."( Clofibrate in combination with phototherapy for unconjugated neonatal hyperbilirubinaemia.
Gholitabar, M; Lai, R; Manning, D; McGuire, H; Rennie, J, 2012
)
2.09
"We included trials where neonates with hyperbilirubinaemia received either clofibrate in combination with phototherapy or phototherapy alone or placebo in combination with phototherapy."( Clofibrate in combination with phototherapy for unconjugated neonatal hyperbilirubinaemia.
Gholitabar, M; Lai, R; Manning, D; McGuire, H; Rennie, J, 2012
)
2.05
"There are insufficient data from different countries on the use of clofibrate in combination with phototherapy for hyperbilirubinaemia to make recommendations for practice."( Clofibrate in combination with phototherapy for unconjugated neonatal hyperbilirubinaemia.
Gholitabar, M; Lai, R; Manning, D; McGuire, H; Rennie, J, 2012
)
2.06

Bioavailability

The bioavailability and the pharmacokinetics of three hypolipidemic marketed drugs have been investigated in seven healthy male volunteers. The absorption rate of carnitine in small intestine was markedly higher in rats treated with clofibrate than in those treated without it.

ExcerptReferenceRelevance
" In addition, the bioavailability and the rate of absorption of clofibrate tended to be higher in this group than in the resistant patients."( Pharmacokinetics of clofibrate in familial hypercholesterolemia.
Boulet, L; Davignon, J; Pichardo, R, 1977
)
0.82
" Diosgenin did not affect the bioavailability of CPIB."( Combined effects of clofibrate and diosgenin on cholesterol metabolism in rats.
Cayen, MN; Dvornik, D, 1978
)
0.58
" After concomitant single-dose administration, the serum p-chlorophenoxyisobutyric acid levels, bioavailability parameters, and pharmacokinetic parameters investigated provided no evidence for an interaction and suggested that colestipol and clofibrate can be administered concomitantly or at separated in tervals according to whichever dosage regimen is deemed advisable by the physician."( The effect of colestipol hydrochloride on the bioavailability and pharmacokinetics of clofibrate.
Albert, KS; DeSante, KA; DiSanto, AR; Vecchio, TJ; Weber, DJ; Welch, RD,
)
0.54
" Applications are given to a comparative bioavailability trial for attainment of steady state levels and to a clinical trial to compare the effects of two hypolipidemics."( The analysis of the two-period repeated measurements crossover design with application to clinical trials.
Fisher, AC; Wallenstein, S, 1977
)
0.26
"The bioavailability of clofibric acid from formulations containing calcium clofibrate along and mixed with calcium carbonate (1:1 w/w) was compared to that from a standard clofibrate formulation in a crossover study in 12 human subjects."( Plasma concentrations and bioavailability of clofibric acid from its calcium salt in humans.
Chasseaud, LF; Taylor, T, 1977
)
0.49
"The bioavailability and the pharmacokinetics of three hypolipidemic marketed drugs: clofibride, clofibrate and basic aluminium salt of p-chlorophenoxyisobutyric acid (CPIB), releasing in vivo p-chlorophenoxyisobutyric acid (CPIB), the active metabolite, have been investigated in seven healthy male volunteers."( Pharmacokinetic study and bioavailability of three marketed compounds releasing p-chlorophenoxyisobutyric acid (CPIB) in volunteers.
Desager, JP; Harvengt, C, 1976
)
0.47
"To obtain information as to a suitable formulation of ethyl 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)-phenyl]propionate (AL-294), an antihyperlipidemic drug of low water solubility, the bioavailability after its oral administration in various dosage forms was evaluated in rats and dogs."( Gastro-intestinal absorption of ethyl 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionate from different dosage forms in rats and dogs.
Iga, K; Ogawa, Y; Shimamoto, T; Toguchi, H; Yashiki, T, 1990
)
0.28
" The bioavailability under this condition was very similar to that under the bile fistula condition, whereas the absorption of AL-294 acid did not decrease when the pancreatic juice was excluded."( Effects of physiological factors on the bioavailability of ethyl 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionate in an emulsion in rats.
Iga, K; Ogawa, Y; Shimamoto, T; Toguchi, H, 1990
)
0.28
" The bioavailability of these moieties in etofibrate was compared to that from equimolar amounts of these drugs administered alone to rhesus monkeys (clofibric acid 354 mg, nicotinic acid 203 mg)."( Bioavailability studies of etofibrate in rhesus monkeys.
Chasseaud, LF; Schatton, W; Taylor, T; Waller, AR, 1985
)
0.27
"The relative bioavailability of 2-(p-chlorophenoxy)-2-methylpropionic acid [2-(nicotinyloxy)-ethyl]-ester (etofibrate) from Lipo-Merz retard (500 mg) with respect to Lipo-Merz (600 mg) has been determined in 10 health volunteers in a crossover study."( Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
Hoppe, HJ; Johnson, KI; Schatton, W, 1984
)
0.27
" As a class, these drugs are generally well absorbed from the gastrointestinal tract (immediate-acting fenofibrate being the exception) and display a high degree of binding to albumin."( Clinical pharmacokinetics of fibric acid derivatives (fibrates).
Miller, DB; Spence, JD, 1998
)
0.3
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Clofibrate required a dosage of 180 mg/kg to suppress the tyloxapol effect. The serum p-chlorophenoxyisobutyric acid levels, bioavailability parameters, and pharmacokinetic parameters investigated provided no evidence for an interaction.

ExcerptRelevanceReference
" The patients were divided into two groups at random and in each case received 3 X 50, 3 X 100, 3 X 150 and 3 X 200 mg bezafibrate daily in increasing or falling dosage for four weeks."( [Dose-effects studies with bezafibrate in patients with hypercholesterolemia and hypertriglyceridemia (author's transl)].
Adam, O; Lang, PD; Wolfram, G; Zöllner, N, 1979
)
0.26
"Clofibrate and m-Inositolnicotinate in a daily dosage of 1,5 g Clofibrate and 1,2 g m-Inositolnicotinate during long term treatment effected a good triglyceride fall in all three lipoprotein fractions, especially in VLDL."( [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
Schwartzkopff, W; Zschiedrich, M, 1978
)
1.93
" The most appropriate drug, clofibrate, is renally excreted and can be used safely if the dosage is markedly reduced."( Uremic hyperlipidemia: the nature of the problem.
Brunzell, JD; Sherrard, DJ, 1977
)
0.55
" Nicotinic acid in the form of niceritrol had another type of dose-response in type II with doses from 3 to 6 g/day."( Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
Carlson, LA; Olsson, AG; Orö, L; Rössner, S, 1975
)
0.6
" Patients receiving clofibrate and both estrogen dosage groups had the highest incidence of cholecystitis or cholelithiasis."( Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project.
, 1977
)
0.58
" Clofibrate required a dosage of 180 mg/kg to suppress the tyloxapol effect."( Metabolic effects of a new hypolipidemic agent, ciprofibrate.
Arnold, A; Beyler, AL; McAuliff, MP, 1979
)
1.17
" Rats fed the same dosage for 14 consecutive days exhibited electromyographic discharges consistent with profound myotonia."( Involvement of transverse tubules in induced myotonia.
Adibi, SA; Martin, JL; Ontell, M; Paul, HS, 1979
)
0.26
" After concomitant single-dose administration, the serum p-chlorophenoxyisobutyric acid levels, bioavailability parameters, and pharmacokinetic parameters investigated provided no evidence for an interaction and suggested that colestipol and clofibrate can be administered concomitantly or at separated in tervals according to whichever dosage regimen is deemed advisable by the physician."( The effect of colestipol hydrochloride on the bioavailability and pharmacokinetics of clofibrate.
Albert, KS; DeSante, KA; DiSanto, AR; Vecchio, TJ; Weber, DJ; Welch, RD,
)
0.54
" The dosage of the single components is this combined therapy is significantly lower than the doses usually used for clofibrate or mesoinositol-hexanicotinate."( [Clinical study with a new antihyperlipemic combination].
Pistautz, H, 1977
)
0.47
" As a consequence, shorter dosing intervals of these drugs seems to be advisable, rather than a reduction in the total daily dose."( Drug protein binding and the nephrotic syndrome.
Azarnoff, DL; Gugler, R, 1976
)
0.26
"The absorption, blood level and renal excretion of chlorphenoxyisobutyric acid (clofibric acid) were examined following oral dosage of the magnesium salt (magnesium clofibrate) in a combination preparation containing meso-inositol hexanicotinate."( [Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate].
el Eisch, IA; Paltauf, F; Pristautz, H, 1977
)
0.45
" The daily dosage was 3 X 1 tablet."( [Clinical experiences with vasoatherolip in early cerebral insufficiency].
Kronenwerth, D; Wallerstein, PV, 1976
)
0.26
"The dose-response effects of clofibrate and niceritrol on serum cholesterol and triglycerides (TG) were studied in 29 patients with Type IIa and IIb hyperlipoproteinaemia."( Dose-response effect of single and combined clofibrate (Atromidin) and niceritrol (Perycit) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia.
Olsson, AG; Orö, L; Rössner, S,
)
0.68
" These findings represent the first report assessing the in-vivo interaction potential of structurally similar and dissimilar peroxisome proliferators and provides insight into the dose-response nature of joint exposures to certain non-genotoxic carcinogens."( Effects of joint exposures to selected peroxisome proliferators on hepatic acyl-CoA oxidase activity in male B6C3F1 mice.
Baldwin, LA; Calabrese, EJ; Leonard, DA; Ochs, JB, 1992
)
0.28
"To obtain information as to a suitable formulation of ethyl 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)-phenyl]propionate (AL-294), an antihyperlipidemic drug of low water solubility, the bioavailability after its oral administration in various dosage forms was evaluated in rats and dogs."( Gastro-intestinal absorption of ethyl 2-chloro-3-[4-(2-methyl-2-phenylpropyloxy)phenyl]propionate from different dosage forms in rats and dogs.
Iga, K; Ogawa, Y; Shimamoto, T; Toguchi, H; Yashiki, T, 1990
)
0.28
" We studied the effects of acute oral dosing with clofibrate (500 mg four times daily) on 24 h intragastric acidity and plasma gastrin concentration in 12 healthy female subjects."( Clofibrate raises human 24 h intragastric acidity but does not affect plasma gastrin concentration.
Gavey, CJ; Nwokolo, CU; Pounder, RE; Smith, JT, 1990
)
1.97
" It is concluded that, from a pharmacokinetic point of view, a reduction in the dosage of ciprofibrate should be considered in patients with a glomerular filtration rate below 30 ml min-1/1."( The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
Bernard, N; Cuisinaud, G; Ferry, N; Gardes, E; Labeeuw, M; Pozet, N; Sassard, J; Zech, PY, 1989
)
0.28
"2 mmol/kg body wt, twice a day) produced significant elevations in fasting serum glucose levels, but this dosage of 4-CP did not alter serum lipid and lipoprotein parameters, whereas clofibrate significantly reduced serum total cholesterol and high density lipoprotein cholesterol levels."( Pharmacologic effects of 4-chlorophenol in rats: comparison to clofibrate.
Feller, DR; Hanson, JM; Newman, HA; Patel, ST; Phornchirasilp, S; Witiak, DT, 1989
)
0.71
" Dose-response and time-course studies revealed that all three genes were regulated coordinately in liver."( The rat clofibrate-inducible CYP4A subfamily. II. cDNA sequence of IVA3, mapping of the Cyp4a locus to mouse chromosome 4, and coordinate and tissue-specific regulation of the CYP4A genes.
Gonzalez, FJ; Hardwick, JP; Kimura, S; Kozak, CA, 1989
)
0.71
" Radioactivity was rapidly taken up by the liver and to a lesser extent by the brown fat within 9 h after oral dosing of ciprofibrate."( In vivo distribution of a carcinogenic hepatic peroxisome proliferator: whole-body autoradiography of [14C]ciprofibrate in the mouse.
Marlowe, C; Rao, MS; Reddy, JK; Waddell, WJ, 1989
)
0.28
"2-fold) but not clofibrate or bezafibrate when dosed PO at 50 mg/kg for 2 weeks in cholesterol-fed rats."( Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Krause, BR; Newton, RS, 1986
)
0.62
"As a basis for establishing dosing guidelines in order to avoid side effects due to overdosage, the concentrations of total and free non-protein bound clofibrinic acid (CA) were determined before and after the administration of a single clofibrate dose (0, 2, 6, 12, 24, 48, 72, 96h) in patients with various degrees of impaired renal function and in a control group (n = 56)."( Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
Graben, N; Hartmann, H; Merk, W; Nikolaus, C; Schlierf, G; Schwandt, P, 1987
)
0.46
" Further studies will allow to define the exact dosage according to gestational age."( [Preventive treatment of jaundice in premature newborn infants with clofibrate. Double-blind controlled therapeutic trial].
Benattar, C; Dehan, M; Delaporte, B; Gabilan, JC; Gerbet, D; Leluc, R; Lindenbaum, A; Magny, JF, 1985
)
0.5
"Two series of nitrogen-substituted cyclic and acyclic imides were examined for hypolipidemic activity in mice after dosing for 16 days at a dose of 20 mg/kg per day."( Comparison of the hypolipidemic activity of cyclic vs. acyclic imides.
Chapman, JM; Cocolas, GH; Hall, IH; Voorstad, PJ; Wyrick, SD, 1985
)
0.27
" The study, followed-up as an open trial using higher doses (100 or 200 mg/day ciprofibrate, 400 mg/day fenofibrate) tried to demonstrate clearly the benefit of therapy after 9 months with the 2 drugs and to establish the dose-response effects."( Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J, 1985
)
0.27
" The conventional daily dosage of 2 g clofibrate failed to control the symptoms of this patient; in order to obtain an adequate response the dosage had to be increased to 4 g daily."( Halofenate versus clofibrate in the management of true diabetes insipidus.
Davignon, J; Gattereau, A; Lewis, W; Verdy, M, 1974
)
0.86
"2-[4(2,2- Dichlorocyclopropyl )phenoxy]2-methyl propionic acid (ciprofibrate), a peroxisome proliferator , induced hepatocytes in the pancreas of adult male F-344 rats when added to their diet at a dosage of 10 mg/kg body weight for 60-72 wk."( Induction and origin of hepatocytes in rat pancreas.
Lalwani, ND; Qureshi, SA; Rao, MS; Reddy, JK; Reddy, MK; Scarpelli, DG, 1984
)
0.27
" The effects of cholestyramine rapidly disappeared when it was withdrawn from the diet, while the effects of gemfibrozil persisted after dosage was stopped."( Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.
Maxwell, RE; Nawrocki, JW; Uhlendorf, PD, 1983
)
0.53
" The drug was administered at four dosage levels during induction of arteriosclerosis in order to establish a possible dose-effect relationship."( Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
Badimón, JJ; Cánovas, M; Padró, T; Vidal, M; Villaverde, CA, 1983
)
0.27
" at an overall dosage of 1275 mg/kg, 2-(p-chlorophenoxy)propionic acid (0."( Effect of phenoxy acids on rat liver regeneration.
Gershbein, LL, 1984
)
0.27
"In a single-blind study the lipid-lowering drug gemfibrozil was compared at fixed dosage of 1600 mg daily with placebo and other drugs (mainly clofibrate) over a nine month period in 33 patients with hyperlipidaemia."( The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Nye, ER; Sutherland, WH; Temple, Wa, 1980
)
0.69
" These findings suggest that there is an optimum dosage of probucol to lower LDL + VLDL cholesterol and the atherogenic index, and that the actual optimum dosage for the beneficial effect depends on blood lipid levels or types of hyperlipidemia."( Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
Abiko, Y; Nakayasu, T; Tawara, K; Tomikawa, M, 1981
)
0.26
" With a dosage of 200 mg daily the effects were maintained for the following period of 6 months."( Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson, AG; Orö, L, 1982
)
0.26
" Since the apparent volumes of distribution were in the same range for both drugs, the amount of drug present in the organism in steady-state also differed by a factor of approximately 30 under the usual dosage regimen."( Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
Abshagen, U; Marinow, J; Spörl-Radun, S, 1980
)
0.53
" Adequate dosage in RDT patients was found to be 200mg every 3rd day."( Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Grützmacher, P; Lang, W; Scheuermann, E, 1981
)
0.26
" An individualized dosage of bezafibrate and repeated checks of the serum concentrations of the drug are recommended during long-term treatment of uremic patients."( Treatment of uremic hypertriglyceridaemia with bezafibrate.
Anderson, P; Norbeck, HE, 1982
)
0.26
" All patients were dietary adapted before the preliminary wash-out period of 4 weeks and received etofylline clofibrate in a dosage of 500 mg/day (2x1 capsule) over 4 weeks, and 750 mg/day (3 x 1 capsule) over further 4 months."( [Clinical effects and tolerance of etofylline clofibrate].
Metz, G; Specker, M; Ziegler, WJ, 1980
)
0.73
" In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate."( [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Hausmann, L; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980
)
0.86
" The drug was further evaluated in a study comprising 56 patients, which combined a dose-response trial with a subsequent comparison between the optimal fenofibrate dose and a clofibrate dose of 2 g/day."( Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
Orö, L; Rössner, S,
)
0.55
"Ethyl 5-(p-chlorophenoxy)-3-hydroxy-3-methylpentanoate (HMP), a new hypocholesterolemic compound, was evaluated in male rats at dosage levels ranging from 25-800 mg/kg/day and in SEA Japanese quail at approximately 200 mg/kg/day."( Activity of ethyl 5-(p-chlorophenoxy)-3-hydroxy-3-methylpentanoate, a new hypocholesterolemic compound, in male rats and SEA Japanese quail.
Day, CE; Heyd, WE; Phillips, WA; Schurr, PE; Stevens, TJ,
)
0.13
" Under the same experimental conditions clofibrate presents a poor dose-response correlation on plasma lipids and generally appears at least 10 times less active than LR 19731 on cholesterol but more effective on liver weight."( Metabolic disorders associated with hyperlipemia: activity of an extremely potent hypolipemic agent (LR 19731).
Fregnan, GB; Frigerio, L; Porta, R, 1981
)
0.53
" Thus, when treating hyperlipoproteinaemia in patients with impaired renal function, the dosage of bezafibrate must be individualized because of its reduced renal elimination."( Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
Anderson, P; Norbeck, HE, 1981
)
0.26
" The optimal dosage of clofibrate which blocked the effect of thrombin of fibrinogen synthesis was 100 mg/kg day."( Suppression of acute-phase synthesis of fibrinogen by a hypolipidemic drug (clofibrate).
Pickart, L, 1981
)
0.8
" The dosage reduction from the usual clofibrate dose of 14 g/week avoided toxicity and corrected the abnormalities in serum triglyceride and high density lipoprotein cholesterol levels to or toward normal."( Chronic clofibrate therapy in maintenance hemodialysis patients.
Brunzell, JD; Goldberg, AB; Haas, LB; Sherrard, DJ, 1980
)
0.97
" Lipo-Merz retard was administered in a dosage of one capsule/day, the combination product in a dosage of one capsule three times daily."( [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
Steger, W, 1980
)
0.26
" One was designed to compared rat liver cell ultrastructure during and after 91 d of dosing with probucol, a hypocholesterolemic agent, and clofibrate, a hypolipidemic drug known to elicit marked alteration of rat hepatocellular morphology."( Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidemic agents probucol, clofibrate, and fenofibrate.
Barnard, SD; Caldwell, WJ; LeBeau, JE; Molello, JA, 1980
)
0.68
"In a randomised blind study with 404 patients 1 capsule Etofibrate per day (500 mg) in sustained release dosage form was tested in comparison to other lipid-lowering drugs."( [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
Füsgen, I; Summa, JD, 1980
)
0.26
"Thirty male patients with hypersyslipidemia (hyperlipemia involving both total lipids and the different lipemic fractions) were treated for 60 days with clofibrate at the dosage of 2 g/day in two administrations."( [Clinical and therapeutic evaluation of a new antilipemic substance].
de Aguiar Magano, L,
)
0.33
" Dose-response comparison of RG 7152 with the tetrazole-substituted leukotriene D4 antagonist LY 171883 to be slightly more potent than RG 7152."( Induction of peroxisomal enzymes by a tetrazole-substituted 2-quinolinylmethoxy leukotriene D4 antagonist.
Groth-Watson, A; Kelley, M; Knoble, D; Kornbrust, D, 1994
)
0.29
" It was strictly dependent on Mg2+ and showed a sigmoidal dose-response for Mg2+ with an S0."( Inorganic pyrophosphatase of clofibrate-induced rat liver peroxisomes.
Ohkuma, S; Shimizu, S, 1993
)
0.58
"5 of gestation were dosed intraperitoneally with 300 mg."( Placental transfer of the hypolipidemic drug, clofibrate, induces CYP4A expression in 18.5-day fetal rats.
Brammar, WJ; Cockcroft, N; Elcombe, CR; Pratten, MK; Simpson, AE, 1996
)
0.55
" This was accompanied by elevated biliary APAP-GSH content in CFB-pretreated mice at 2 hr after APAP dosing with diminished levels in bile at 12 hr."( Protection by clofibrate against acetaminophen hepatotoxicity in male CD-1 mice is associated with an early increase in biliary concentration of acetaminophen-glutathione adducts.
Cohen, SD; Hoivik, DJ; Khairallah, EA; Manautou, JE; Tveit, A, 1996
)
0.65
" The dose-response curve for M6G was shifted to the right by prior administration of M3G."( Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?
Cabanes, CG; Faura, CC; Horga, JF; Olaso, JM, 1996
)
0.29
" Chow-fed rats were orally gavaged daily with a dosing vehicle alone or with 100 mg/kg of each of the fibrates for 1 week and in addition with gemfibrozil for 2 weeks."( Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME, 1995
)
0.29
" Analysis of dose-response exposures to DEHP by reverse transcription (RT)-PCR confirm these results and also shows that GRP58 is not altered in kidney or testis."( A glucose-regulated protein, GRP58, is down-regulated in C57B6 mouse liver after diethylhexyl phthalate exposure.
Gill, SS; Muhlenkamp, CR, 1998
)
0.3
" Male and female Sprague-Dawley (CD) rats were dosed with either pregnenolone-16alpha-carbonitrile (PCN; 50 mg/kg per day for 5 days), phenobarbital (PB; 100 mg/kg per day for 4 days), beta-naphthoflavone (betaNF; 100 mg/kg per day for 3 days), clofibrate (CF; 300 mg/kg per day for 14 days), isoniazid (ISO; 100 mg/kg per day for 3 days), or dexamethasone (DEX; 50 mg/kg per day for 4 days)."( Ethylmorphine N-demethylase activity as a marker for cytochrome P450 CYP3A activity in rat hepatic microsomes.
Amacher, DE; Schomaker, SJ, 1998
)
0.48
" Transfected cells were dosed with several known inducers of CYP3A4 and the levels of SPAP were measured."( A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro.
Gibson, GG; Goldfarb, PS; Gray, TJ; Ogg, MS; Tarbit, M; Williams, JM, 1999
)
0.3
" A fifth group received clofibrate at a dosage of 500 mg/kg/day to provide a positive Control for liver peroxisome activity."( Effects of di-isononyl phthalate (DINP) on peroxisomal markers in the marmoset-DINP is not a peroxisome proliferator.
Hall, M; Harling, R; Matthews, A; Webley, L, 1999
)
0.61
" Typically four rats are dosed for 4 days using oral doses in the range 50-500 mg kg(-1) day(-1)."( Rapid determination of rat hepatocyte mRNA induction potential using oligonucleotide probes for CYP1A1, 1A2, 3A and 4A1.
Evans, DC; Heavens, R; Jack, A; Meneses-Lorente, G; Surry, DD, 2000
)
0.31
" ICG significantly decreased the bile flow rate and biliary concentration of APAP-glutathione, APAP-glucuronide and APAP-mercapturate within the first hour after dosing without affecting the biliary concentration of APAP."( Effects of clofibrate and indocyanine green on the hepatobiliary disposition of acetaminophen and its metabolites in male CD-1 mice.
Chen, C; Hennig, GE; Manautou, JE; McCann, DJ, 2000
)
0.7
" Clofibrate at lower concentrations (10-200 microM) produced increases in the mRNA levels of cPLA(2) in a dose-response manner."( Modulation of cytosolic phospholipase A(2) by PPAR activators in human preadipocytes.
Choy, PC; Dembinski, T; Hatch, GM; Jiang, YJ; Kroeger, EA; Mymin, D, 2001
)
1.22
"SV2 cells; kinetics and dose-response studies established that maximal MCAD gene stimulation was reached 4 h after addition of 50 microM oleate (C18:1) in the culture medium."( Effects of fatty acids on mitochondrial beta-oxidation enzyme gene expression in renal cell lines.
Bastin, J; Djouadi, F; Ouali, F, 2002
)
0.31
" The chemicals were found to differ characteristically in their potency and dose-response relationship to induce FAH when given alone or when administered following initiation with diethylnitrosamine."( Prevalidation of a rat liver foci bioassay (RLFB) based on results from 1600 rats: a study report.
Bannasch, P; Brendler-Schwaab, S; Deml, E; Enzmann, H; Haertel, T; Ittrich, C; Kopp-Schneider, A; Küttler, K; Mellert, W; Mönnikes, O; Oesterle, D; Schladt, L; Schwarz, M,
)
0.13
"A conventional approach to assess cytochrome P450 (CYP) induction in preclinical animal models involves daily dosing for a least a week followed by Western blot and/or enzyme activity analysis."( Assessment of temporal biochemical and gene transcription changes in rat liver cytochrome P450: utility of real-time quantitative RT-PCR.
Alton, K; Chu, I; Goodsaid, FM; Gu, C; Kishnani, NS; Li, Z; Mandakas, G; Montgomery, D; Norton, L; Palamanda, JR; Rosenblum, IY; Smith, R; Soares, T; You, X, 2003
)
0.32
"Rats were dosed daily for 8 days with model inducers of CYP1A, CYP2B, CYP3A, or CYP4A."( Assessment of temporal biochemical and gene transcription changes in rat liver cytochrome P450: utility of real-time quantitative RT-PCR.
Alton, K; Chu, I; Goodsaid, FM; Gu, C; Kishnani, NS; Li, Z; Mandakas, G; Montgomery, D; Norton, L; Palamanda, JR; Rosenblum, IY; Smith, R; Soares, T; You, X, 2003
)
0.32
" Male and female neonatal CD-1 mice were dosed with clofibrate at doses of 100, 250, and 500 mg/kg or with the positive control, diethylnitrosamine (DEN), at 2 mg/kg by oral gavage on days 9 and 16 post birth and observed for approximately 1 year for the development of tumors."( Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse.
Allen, JS; Hoivik, DJ; Miller, RT; Nesfield, SR; Rickert, D; Santostefano, MJ; Selinger, K; Williams, TC,
)
0.64
" Primary hepatocytes isolated from mice dosed with CFB are resistant to APAP toxicity."( Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen.
Aleksunes, LM; Kardas, MJ; Klaassen, CD; Manautou, JE; Moffit, JS; Slitt, AL, 2007
)
0.6
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
"Within the scope of the Rat Liver Foci Bioassay the model carcinogens N-nitrosomorpholine (NNM), 2-acetylaminoflouren (2-AAF), phenobarbital (PB), and clofibrate (CF) were analyzed concerning their potency and dose-response relationship to induce foci of altered hepatocytes (FAHs), which are known to be precursor lesions of liver adenoma and carcinoma."( Comparison of mode of action of four hepatocarcinogens: a model-based approach.
Bannasch, P; Groos, J; Kopp-Schneider, A; Schwarz, M, 2007
)
0.54
" It will be important to establish the appropriate dosage of fibrates for treatment against kidney disease and to develop a novel PPARα activator that has a steady serum concentration regardless of kidney dysfunction."( Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration.
Aoyama, T; Ehara, T; Gonzalez, FJ; Hashimoto, K; Higuchi, M; Hora, K; Kamijo, Y; Nakajima, T; Shigematsu, H; Takahashi, K, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Dosing rats with 20 mg/kg or 200 mg/kg of clofibrate decreased the brain accumulation of the P-glycoprotein substrate, verapamil, by 50% (in situ brain perfusion; effects blocked by GW6471) and increased P-glycoprotein expression and activity in capillaries ex vivo."( PPAR-α, a lipid-sensing transcription factor, regulates blood-brain barrier efflux transporter expression.
Campos, CR; Cannon, RE; Chan, GN; Evans, RA; Miller, DS; More, VR; Oliver, KD, 2017
)
0.72
" A proof of concept extension of the MOA framework is proposed for scoring confidence in the supporting data to improve scientific justification for MOA use in characterizing hazards and selecting dose-response extrapolation methods for specific chemicals."( Quantitative weight of evidence to assess confidence in potential modes of action.
Becker, RA; Dellarco, V; Dourson, M; Foreman, J; Kirman, C; Kronenberg, JM; Linkov, I; Manibusan, MK; Meek, B; Palermo, C; Pottenger, LH; Schoeny, R; Seed, J, 2017
)
0.46
" There is increasing interest in the incorporation of epigenetic and metabolic biomarkers to complement apical data; however, a number of questions, including the tissue specificity, dose-response patterns, early detection of those endpoints, and the added value need to be addressed."( Dose-response analysis of epigenetic, metabolic, and apical endpoints after short-term exposure to experimental hepatotoxicants.
Beger, RD; Chalbot, MG; Johnson, K; Kavouras, IG; Koturbash, I; LeBaron, MJ; Lin, H; Miousse, IR; Murphy, LA; Rasoulpour, RJ; Schisler, MR; Schnackenberg, LK; Sun, J; Sura, R, 2017
)
0.46
" This ENU dosing regimen also increased the frequency of CD59-negative erythrocytes."( Applying the erythrocyte Pig-a assay concept to rat epididymal sperm for germ cell mutagenicity evaluation.
Ji, Z; LeBaron, MJ, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
anticholesteremic drugA substance used to lower plasma cholesterol levels.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
PPARalpha agonistA PPAR modulator which activates the peroxisome proliferator-activated receptor-alpha.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (57)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.62340.044717.8581100.0000AID485294
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID2323
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.39810.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.88320.006038.004119,952.5996AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency5.62340.00308.794948.0869AID1347053
GALC proteinHomo sapiens (human)Potency50.118728.183828.183828.1838AID1159614
AR proteinHomo sapiens (human)Potency29.84930.000221.22318,912.5098AID743042
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.51190.001318.074339.8107AID926
regulator of G-protein signaling 4Homo sapiens (human)Potency37.64990.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency23.48500.001310.157742.8575AID1259255
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.68320.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency37.52190.003041.611522,387.1992AID1159552; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency13.36410.000229.305416,493.5996AID743075; AID743079
polyproteinZika virusPotency5.62340.00308.794948.0869AID1347053
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency8.97160.035520.977089.1251AID504332
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.55310.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency0.00700.143427.612159.8106AID1159516
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency39.73760.006026.168889.1251AID488953; AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency0.12590.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.00630.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency14.12541.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.16940.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)65.50000.11007.190310.0000AID1443980; AID1473738
Fatty acid-binding protein, liverRattus norvegicus (Norway rat)Ki6.92000.01501.24876.9200AID407366
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)EC50 (µMol)55.00000.00200.47533.2000AID240312
Fatty acid-binding protein, liverRattus norvegicus (Norway rat)Kd8.66250.01801.78799.6000AID427200; AID427204; AID427206; AID427208; AID427210; AID427212; AID427213; AID427215
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)EC50 (µMol)500.00000.00001.262610.0000AID141913
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)EC50 (µMol)500.00000.00000.764610.0000AID141913
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)EC50 (µMol)500.00000.00000.990510.0000AID141913
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)EC50 (µMol)500.00000.00001.052810.0000AID141913
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)EC50 (µMol)500.00000.00001.160510.0000AID141913
Peroxisome proliferator-activated receptor alphaMus musculus (house mouse)EC50 (µMol)50.00000.00021.397110.0000AID141903
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)500.00000.00000.992210.0000AID240313; AID93033
Peroxisome proliferator-activated receptor gammaMus musculus (house mouse)EC50 (µMol)500.00000.00031.654210.0000AID141913
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)EC50 (µMol)55.00000.00061.607410.0000AID240312; AID677051; AID91237
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (144)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (63)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleoplasmPeroxisome proliferator-activated receptor alphaMus musculus (house mouse)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaMus musculus (house mouse)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (485)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID190777Hypolipidemic activity was determined in male rats, cholesterol was determined in high-density lipoproteins at 30 mg/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID1861627Induction of oxidative stress in KM mouse assessed as reduction in CAT level in plasma at 1.65 mmol/Kg, IG administered via gavage measured for 1 month2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1751034Acute toxicity in Kunming mouse assessed as change in body weight at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1362494Hepatoprotective activity in ICR mouse assessed as centrilobular hypertrophy at 240 umol/kg/day administered po for 2 months by histopathological analysis2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1123127Effect on microsomal protein content in Sprague-Dawley rat at 0.4 mmol/kg, po twice daily for 7 days (Rvb = 25.8 +/- 1.17 mg/g)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID1751038Hepatotoxicity in Kunming mouse assessed as increase in plasma alkaline phosphatase level at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1133149Modulation of ethylmorphine N-demethylase activity in sucrose-fed Sprague-Dawley rat liver microsomes assessed as formaldehyde formation using ethylmorphine as substrate at 0.4 mmol/kg, po bid for 7 days (Rvb = 6.40 to 9.36 nmol/mg/min)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1123126Effect on liver weight in Sprague-Dawley rat at 0.4 mmol/kg, po twice daily for 7 days (Rvb = 11.8 +/- 0.93 g)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID427200Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 5 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID141913Agonist activity for murine PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1134505Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum triglyceride level at 0.25 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID1123123Antilipidemic activity against Sprague-Dawley rat assessed as liver triglyceride level per gram of tissue at 0.4 mmol/kg, po twice daily for 7 days (Rvb = 3.87 +/- 0.59 mg)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID1362478Hypolipidemic activity in Triton WR 1339-induced acute hyperlipidemic ICR mouse model assessed as decrease in total cholesterol levels in plasma at 240 umol/kg, ig for one week followed by Triton WR 1339 challenge on day 6 measured after 24 hrs2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID196328Effect of compound was measured on serum alpha-lipoprotein in male Dawley rats at the dose of 0.4 mmol/kg (day+4).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID503332Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1149894Hypolipidemic activity in CFY Sprague-Dawley rat assessed as liver lipid per gm of liver at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID749046Inhibition of full-length human 11beta-HSD1 expressed in HEK293 cells at 10 uM after 2 hrs by scintillation proximity assay relative to control2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric acid as a potent hypoglycemic agent.
AID1861623Hepatotoxicity in KM mouse assessed as reduction in plasma ALT level at 1.65 mmol/Kg, IG administered via gavage measured for 1 month by automated biochemical analyzer2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID232527Effect of compound was measured on serum heparin-MnCl2 precipated ipoprotein Dawley rats at 0.4 mmol/kg dose(day-1).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID172197Compound was tested for effect on body weight after oral administration of 100 mg/kg in male rats.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID1144581Hypocholesterolemic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered via intubation measured on day 4 by Liebermann-Burchard reaction (Rvb = 100%)1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Hypocholesterolemic activity of 1,3-bis(substituted phenoxy)-2-propanones.
AID186011Effect on liver weight was measured on treated rats at a dose of 0.5 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID1144507Hypocholesterolemic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered via intubation measured on day 4 by Liebermann-Burchard method relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Cycloalkanones. 8. Hypocholesterolemic activity of long-chain ketones related to pentadecanone.
AID1144509Hypocholesterolemic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered via intubation measured on day 16 by Liebermann-Burchard method relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Cycloalkanones. 8. Hypocholesterolemic activity of long-chain ketones related to pentadecanone.
AID1751043Hepatotoxicity in Kunming mouse assessed as induction of oxidative stress by measuring decrease in plasma GSH level at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1151066Antilipidemic activity in triton WR-1339-induced hyperlipidemic Sprague-Dawley rat model assessed as reduction of serum cholesterol level at 0.124 mM/kg relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID1362482Hepatoprotective activity in ICR mouse assessed as serum ALT levels at 240 umol/kg/day administered po for 2 months (Rvb = 36.25 +/- 1.08 U/L)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1673474Antioxidant activity in mouse RAW264.7 cells assessed as reduction in ox-LDL induced ROS accumulation at 10 uM preincubated for 10 mins followed by ox-LDL stimulation and measured after 24 hrs by DCFH-DA staining based fluorescence microscopic analysis2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Anti-atherosclerosis effect of H
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID189228Percent reduction of total cholesterol level in plasma was evaluated 300 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID1362485Antioxidant activity in ICR mouse assessed as serum SOD levels at 240 umol/kg/day administered po for 2 months (Rvb = 337.64 +/- 4.82 U/ml)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID503308Antiproliferative activity against human PC3 cells at 30 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID171420Percent change in plasma triglycerides in cholesterol-fed rats at 200 mg/kg dose given in a period of 3 days1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators.
AID403781Antihyperlipidemic activity in olive oil-treated ddY mouse assessed as serum triglyceride level at 250 mg/kg, po after 6 hrs2005Journal of natural products, Sep, Volume: 68, Issue:9
Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).
AID189234Percent reduction of total cholesterol level in plasma was evaluated at dose 30 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID1130670Hypolipidemic activity in COBBS-CD rat assessed as reduction in serum sterol level at 0.3% administered with chow diet after 5 days relative to control1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
(Aryloxy)[p-(aryloxy)phenyl]- and (aryloxy)[p-(arylthio)phenyl]acetic acids and esters as hypolipidemic agents.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1144579Hypocholesterolemic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered via intubation measured on day 16 by Liebermann-Burchard reaction (Rvb = 100%)1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Hypocholesterolemic activity of 1,3-bis(substituted phenoxy)-2-propanones.
AID1133130Drug metabolism in Sprague-Dawley rat serum assessed as esterase-mediated hydrolysis measured after 5 mins1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1147265Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 1693 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID173715In vivo hypolipidemic activity, expressed as percent decrease in Triglyceride in rat, at dosage of 100 mg for 7 days.1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
AID111620Hypotriglyceridemic activity of KK-mice in 12 animals1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID172203Compound was tested for effect on serum LDL after oral administration of 100 mg/kg in male rats1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID173720Hypolipidemic activity expressed as percentage decrease in triglyceride in rat, at dosage of 50 mg for 7 days1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
AID1132581Hypocholesteremic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered for 4 days measured 24 hrs after last dose by Liebermann-Burchard method (Rvb = 100 +/- 8%)1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID171408Percent change in plasma HDL cholesterol in cholesterol-fed rats at 200 mg/kg dose given in a period of 3 days1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators.
AID1133144Modulation of triglyceride level in sucrose-fed Sprague-Dawley rat liver at 0.4 mmol/kg, po bid for 7 days (Rvb = 7.26 to 8.29 mg/g)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID128759Hypolipidemic effects in CF1 male mice at a dose 150 mg/(kg day), ip, percent control of serum cholesterol was determined on day 161984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogues.
AID1751042Hepatotoxicity in Kunming mouse assessed as induction of oxidative stress by measuring increase in plasma MDA level at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1133147Modulation of liver weight in sucrose-fed Sprague-Dawley rat at 0.4 mmol/kg, po bid for 7 days (Rvb = 11.30 to 13.16 gms)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1149892Toxicity in CFY Sprague-Dawley rat assessed as body weight gain at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149893Toxicity in CFY Sprague-Dawley rat assessed as relative liver weight at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1145549Hypolipidemic activity in albino Wistar Royal Hart rat assessed as change in plasma cholesterol level at 300 mg/kg, po for 6 days1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Synthesis and biological evaluation of substituted 2,2'-oxybis(propionic acid) derivatives and related compounds.
AID1134507Toxicity in Sprague-Dawley rat assessed as increase in liver weight at 0.25 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID383702Inhibition of serum triglyceride elevation in olive oil-treated ddY mouse at 250 mg/kg, po after 6 hrs2008Journal of natural products, May, Volume: 71, Issue:5
Perennisosides I-VII, acylated triterpene saponins with antihyperlipidemic activities from the flowers of Bellis perennis.
AID128760Hypolipidemic effects in CF1 male mice at a dose 150 mg/(kg day), ip, percent control of serum triglyceride was determined on day 161984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogues.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID326598Agonist activity at mouse PPARalpha receptor in monkey COS7 cells assessed as activation of CAT reporter gene at 50 uM by transactivation assay relative to Wy,14-6432008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID196337Effect of compound was measured on serum total triglycerides in male Dawley rats at the dose of 0.4 mmol/kg (day+10).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1591813Antihyperlipidemic activity in po dosed Sprague-Dawley rat assessed as increase in HDL-C level administered twice daily for 1 week measured 2 hrs post-last dose by HPLC analysis relative to control2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208.
AID1673475Antioxidant activity in mouse RAW264.7 cells assessed as reduction in ox-LDL induced oxidative stress by measuring decrease in MDA level at 10 to 50 uM preincubated for 10 mins followed by ox-LDL stimulation and measured after 24 hrs2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Anti-atherosclerosis effect of H
AID188382Hypolipidemic activity was expressed as percent decrease in triglycerides1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds.
AID188890Percent increase in liver weight in plasma was evaluated 30 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID1150282Reduction in sterol level in CFE rat assessed as sterol in serum at 0.3% of diet treated through diet for 6 days relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Hypolipidemic alkoxybenzoic acids.
AID1474087Ratio of drug concentration at steady state in human at 2 g, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1861625Hepatotoxicity in KM mouse assessed as reduction in total bilirubin level in plasma at 1.65 mmol/Kg, IG administered via gavage measured for 1 month by automated biochemical analyzer2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1362483Hepatoprotective activity in ICR mouse assessed as serum APK levels per 100 ml at 240 umol/kg/day administered po for 2 months (Rvb = 20.02 +/- 0.61 U)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID383698Inhibition of serum triglyceride elevation in olive oil-treated ddY mouse at 125 mg/kg, po after 4 hrs2008Journal of natural products, May, Volume: 71, Issue:5
Perennisosides I-VII, acylated triterpene saponins with antihyperlipidemic activities from the flowers of Bellis perennis.
AID1147267Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 304 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID1132584Toxicity in Sprague-Dawley rat at 10 mg/kg/day, po1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID193995Effect of compound on liver CH levels in male Dawley rats at the dose of 0.4 mmol/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID383700Inhibition of serum triglyceride elevation in olive oil-treated ddY mouse at 250 mg/kg, po after 2 hrs2008Journal of natural products, May, Volume: 71, Issue:5
Perennisosides I-VII, acylated triterpene saponins with antihyperlipidemic activities from the flowers of Bellis perennis.
AID503335Inhibition of of c-Jun expressed in HEK293 cells assessed as induction of protein interaction in presence of camptothecin with Pin1 by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1133137Antilipidemic activity in sucrose-fed Sprague-Dawley rat assessed as serum triglyceride level at 0.4 mmol/kg, po bid for 7 days measured on day 0 (Rvb = 157.1 +/- 77.8 mg/dL)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1591814Antihyperlipidemic activity in po dosed Sprague-Dawley rat assessed as decrease in triglyceride level administered twice daily for 1 week measured 2 hrs post-last dose by GPO-PAP analysis relative to control2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208.
AID1133170Antilipidemic activity in 48-hrs starved normal Sprague-Dawley rat model assessed as plasma cholesterol level at 0.124 mmol/kg, po (Rvb = 88.7 +/- 6.9 mg/dL)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1133139Antilipidemic activity in sucrose-fed Sprague-Dawley rat assessed as serum cholesterol level at 0.4 mmol/kg, po bid for 7 days measured on day 0 (Rvb = 69 +/- 9 mg/dL)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1362489Antioxidant activity in ICR mouse assessed as hepatic GSSG levels at 240 umol/kg/day administered po for 2 months (Rvb = 2.91 +/- 0.31 microM)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID173725Hypolipidemic activity, expressed as percent decrease in serum cholesterol in rat, at dosage of 100 mg for 7 days by Zak et al method1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
AID1132582Hypocholesteremic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered for 10 days measured 24 hrs after last dose by Liebermann-Burchard method (Rvb = 100 +/- 10%)1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID1147535Inhibition of fatty acid biosynthesis in Ad Lib fed Wistar rat liver assessed as sodium [1-14C]acetate incorporation at 261 mg/kg/day administered through diet for 7 days measured 1 hr after labeled acetate challenge by liquid scintillation spectrometry (1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID503333Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1147533Inhibition of cholesterol biosynthesis in meal fed Wistar rat liver assessed as sodium [1-14C]acetate incorporation at 188 mg/kg/day administered through diet for 7 days measured 1 hr after labeled acetate challenge by liquid scintillation spectrometry (R1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID1151068Antilipidemic activity in triton WR-1339-induced hyperlipidemic Sprague-Dawley rat model assessed as reduction of serum triglyceride level at 0.124 mM/kg relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID1133141Antilipidemic activity in sucrose-fed Sprague-Dawley rat assessed as serum cholesterol level at 0.4 mmol/kg, po bid for 7 days measured on day 7 (Rvb = 92 +/- 22 mg/dL)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1362475Hepatoprotective activity in ICR mouse assessed as liver coefficient at 240 umol/kg/day administered po for 2 months (Rvb = 40.50 +/- 0.71 mg/g)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1147165Hypolipidemic activity in Wistar rat assessed as reduction in plasma triglyceride level at 766 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID172357Effect on serum Triglycerides was determined in normal rats at a dose of 1 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID182663Ability to inhibit collagen -induced platelet aggregation in male SD rats; <101988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds.
AID383697Inhibition of serum triglyceride elevation in olive oil-treated ddY mouse at 125 mg/kg, po after 2 hrs2008Journal of natural products, May, Volume: 71, Issue:5
Perennisosides I-VII, acylated triterpene saponins with antihyperlipidemic activities from the flowers of Bellis perennis.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID196330Effect of compound was measured on serum alpha-lipoprotein in male Dawley rats at the dose of 0.4 mmol/kg (day-1).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1861620Hepatotoxicity in KM mouse assessed as effect on liver weight at 1.65 mmol/Kg, IG administered via gavage measured for 1 month2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1861621Hepatotoxicity in KM mouse assessed as reduction in liver coefficient at 1.65 mmol/Kg, IG administered via gavage measured for 1 month2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID91237Agonist activity for Human PPAR alpha receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID189355Percent reduction of triglyceride level in plasma was evaluated 300 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID1133171Antilipidemic activity in 48-hrs starved normal Sprague-Dawley rat model assessed as plasma triglyceride level at 0.124 mmol/kg, po (Rvb = 20.8 +/- 5.5 mg/dL)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1861640Hepatotoxicity in KM mouse assessed as nuclear degeneration at 1.65 mmol/Kg, IG administered via gavage by H and E staining based analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1362492Hepatoprotective activity in ICR mouse assessed as hypertrophy at 240 umol/kg/day administered po for 2 months by histopathological analysis2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID191261Hypolipidemic activity was determined in male rats, and low-density lipoprotein level was determined at 100 mg/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID403774Antihyperlipidemic activity in olive oil-treated ddY mouse assessed as serum triglyceride level at 125 mg/kg, po after 2 hrs2005Journal of natural products, Sep, Volume: 68, Issue:9
Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).
AID1362474Hepatoprotective activity in ICR mouse assessed as liver weight at 240 umol/kg/day administered po for 2 months (Rvb = 1.49 +/- 0.42 g)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1151085Increase in ethylmorphine N-demethylase activity in sucrose-fed Sprague-Dawley rat model at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1861634Induction of inflammation in KM mouse assessed as upregulation of TNF-alpha expression in liver tissue at 1.65 mmol/Kg, IG administered via gavage measured for 1 month by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1751044Hepatotoxicity in Kunming mouse assessed as induction of inflammatory response by measuring upregulation of TNF-alpha level in liver at 300 mg/kg, ig for 1 month by western blot analysis2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID503334Effect on p53 expressed in HEK293 cells assessed as effect on p53-p53 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID427213Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 15 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID109864Hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg per day, serum triglyceride measured on the 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1673478Anti-inflammatory activity in mouse RAW264.7 cells assessed as decrease in ox-LDL induced inflammatory reaction by measuring increase in IL-10 production at 10 to 50 uM preincubated for 10 mins followed by ox-LDL stimulation and measured after 24 hrs2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Anti-atherosclerosis effect of H
AID173870Tested for the hypolipidemic activity, expressed as percent decrease in serum cholesterol in rat, at dosage of 50 mg for 7 days1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
AID186008Effect on liver weight was measured on control rats at a dose of 0.05 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID1133151Modulation of cytochrome-P450 activity in sucrose-fed Sprague-Dawley rat liver microsomes at 0.4 mmol/kg, po bid for 7 days measured per mg of protein (Rvb = 0.477 to 0.593 nmol)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID172201Compound was tested for effect on serum HDL after oral administration of 100 mg/kg in male rats1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID190141Hypolipidemic effects in rat plasma Triglyceride (TG) by peroral administration at 100 mg/kg dose1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID1134503Hypolipidemic activity in Sprague-Dawley rat assessed as reduction in serum cholesterol level at 0.25 % compound administered in diet for 14 days relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hypolipidemic arylthioalkanoic acids.
AID326600Agonist activity at mouse PPARalpha receptor in monkey COS7 cells assessed as activation of CAT reporter gene at 300 uM by transactivation assay relative to Wy,14-6432008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID503336Effect on cofilin1 expressed in HEK293 cells assessed as effect on cofilin1; Limk2 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID196329Effect of compound was measured on serum alpha-lipoprotein in male Dawley rats at the dose of 0.4 mmol/kg (day+7).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID403782Antihyperlipidemic activity in olive oil-treated ddY mouse assessed as serum triglyceride level at 500 mg/kg, po after 6 hrs2005Journal of natural products, Sep, Volume: 68, Issue:9
Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).
AID173235Percent change in triglyceride concentration in serum from hypercholesterolemic rats at dose 200 mg/kg (po)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID1144508Hypocholesterolemic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered via intubation measured on day 10 by Liebermann-Burchard method relative to control1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Cycloalkanones. 8. Hypocholesterolemic activity of long-chain ketones related to pentadecanone.
AID1149375Hypolipidemic activity in normal rat assessed as reduction in cholesterol level at 0.2 % administered in diet for 5 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Potential hypolipidemic agents derived from 3-hydroxy-17,17-dimethylgona-1,3,5(10),8,11,13-hexaene.
AID1673472Anti-atherosclerotic activity in mouse RAW264.7 cells assessed as decrease in ox-LDL induced intracellular lipid accumulation by measuring reduction in total cholesterol level at 10 to 50 uM preincubated for 10 mins followed by ox-LDL stimulation and meas2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Anti-atherosclerosis effect of H
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1123124Inhibition of Sprague-Dawley rat liver microsome HMG-CoA reductase activity assessed as mevalonic acid formation form DL-3-hydroxy-3-methylglutaryl[3-14C]coenzyme by scintillation counting (Rvb = 13.2 +/- 3.30 nmol/mg/h)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID111641In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID383704Inhibition of serum triglyceride elevation in olive oil-treated ddY mouse at 500 mg/kg, po after 4 hrs2008Journal of natural products, May, Volume: 71, Issue:5
Perennisosides I-VII, acylated triterpene saponins with antihyperlipidemic activities from the flowers of Bellis perennis.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1151087Increase in NADPH cytochrome c reductase activity in sucrose-fed Sprague-Dawley rat model at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID1751035Hepatotoxicity in Kunming mouse assessed as increase in hepatic weight at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1132585Estrogenic activity in Sprague-Dawley rat at 10 mg/kg/day, po1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID190776Hypolipidemic activity was determined in male rats, cholesterol was determined in high-density lipoproteins at 100 mg/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID1591809Inhibition of BRD4 bromodomain 2 (unknown origin) incubated for 30 mins by ELISA2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208.
AID184106Liver weight in Wistar-Imamichi rats at 200 mg/Kg dose in 12 rats1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1362473Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1147164Hypolipidemic activity in Wistar rat assessed as reduction in plasma triglyceride level at 1693 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID1151092Effect on cytochrome P450 level in sucrose-fed Sprague-Dawley rat model assessed per mg of protein at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1132583Hypocholesteremic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered for 16 days measured 24 hrs after last dose by Liebermann-Burchard method (Rvb = 100 +/- 9%)1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
Effects of molecular modification on hypocholesteremic activity of 1,3-bis(substituted phenoxy)-2-propanones and related derivatives.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1751036Hepatotoxicity in Kunming mouse assessed as increase in plasma aspartate transaminase level at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID231070Percent change in high density lipoprotein cholesterol in hypercholesterolemic rats1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID427206Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 37 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID186009Effect on liver weight was measured on control rats at a dose of 0.5 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID188888Percent decrease in triglyceride (TG) after 7 days at 0.05 percent in the diet of SD male rats in comparison to control animals1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and hypolipidemic activities of 5-thienyl-4-oxazoleacetic acid derivatives.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID173046Percent change in low density lipoproteins cholesterol concentration in serum from hypercholesterolemic rats at dose 200 mg/kg (po)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID1147354Increase in liver weight in Wistar rat at 766 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1751033Hypolipidemic activity in TritonWR1339-induced hyperlipidemic Kunming mouse model assessed as reduction in plasma TC level at 0.362 mmol/kg, ig administered for 7 days2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID172355Effect on serum Triglycerides was determined in normal rats at a dose of 0.1 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID188891Percent increase in liver weight in plasma was evaluated 300 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID1861646Upregulation of p-NF-kappaB p65 protein expression in liver of KM mouse at 1.65 mmol/Kg, IG administered via gavage measured after 1 month by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1150284Reduction in triglyceride level in CFE rat assessed as sterol in serum at 0.3% of diet treated through diet for 6 days relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Hypolipidemic alkoxybenzoic acids.
AID109866Compound was evaluated for the hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg per day intraperitoneally of serum cholesterol at 9th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID171418The compound was tested for % change in plasma total cholesterol in normocholesterolemic rats at 0.2 % composition of dose with diet given in a period of 7 days1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators.
AID1147266Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 766 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID1474086Drug concentration at steady state in human at 2 g, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1147356Increase in liver weight in Wistar rat at 119 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID503340Inhibition of p53 expressed in HEK293 cells assessed as effect on p53-p53 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1151090Effect on cytochrome b5 level in sucrose-fed Sprague-Dawley rat model assessed per mg of protein at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose (Rvb = 0.184 +/- 0.023 nmol)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID427208Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 30 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID1751050Hepatotoxicity in Kunming mouse assessed as increase in liver coefficient at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID109861Hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg per day, serum cholesterol measured on the 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID111633In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID403780Antihyperlipidemic activity in olive oil-treated ddY mouse assessed as serum triglyceride level at 125 mg/kg, po after 6 hrs2005Journal of natural products, Sep, Volume: 68, Issue:9
Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).
AID1362479Hypolipidemic activity in Triton WR 1339-induced acute hyperlipidemic ICR mouse model assessed as decrease in malonaldehyde levels in plasma at 240 umol/kg, ig for one week followed by Triton WR 1339 challenge on day 6 measured after 24 hrs2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1147355Increase in liver weight in Wistar rat at 304 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID186018Hypolipidemic effects in rat fed a high cholesterol diet (HC) by peroral administration at 100 mg/kg dose.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID1147268Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 119 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID1362488Antioxidant activity in ICR mouse assessed as hepatic GSH levels at 240 umol/kg/day administered po for 2 months (Rvb = 43.38 +/- 4.59 microM)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1133148Modulation of liver microsomal protein level in sucrose-fed Sprague-Dawley rat at 0.4 mmol/kg, po bid for 7 days measured per gm of tissue (Rvb = 25.0 to 27.2 mg)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1151077Antilipidemic activity in sucrose-fed Sprague-Dawley rat model assessed as reduction in HMG-CoA reductase activity at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID1751041Hepatotoxicity in Kunming mouse assessed as induction of oxidative stress by measuring decrease in plasma CAT level at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID190953Effect on serum Triglycerides was measured on treated rats at a dose of 0.5 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID427215Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 10 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1861628Induction of oxidative stress in KM mouse assessed as reduction in GSH level in plasma at 1.65 mmol/Kg, IG administered via gavage measured for 1 month2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1151073Antilipidemic activity in sucrose-fed Sprague-Dawley rat model assessed as reduction of liver cholesterol level at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose (Rvb = 1.86 +/- 0.17 mg/gm)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID196338Effect of compound was measured on serum total triglycerides in male Dawley rats at the dose of 0.4 mmol/kg (day+14).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1133134Antilipidemic activity in Triton WR-1339-induced hyperlipidemic Sprague-Dawley rat model assessed as plasma triglyceride level at 0.124 mg/kg, po (Rvb = 98.5 +/- 16.9 mg/dL)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID116863Reduction in serum cholesterol in CF1 mice on day 9 following 20 mg/kg i.p. o.d. for 16 days.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Comparison of the hypolipidemic activity of cyclic vs. acyclic imides.
AID196341Effect of compound was measured on serum total triglycerides in male Dawley rats at the dose of 0.4 mmol/kg (day+7).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID116862Reduction in serum cholesterol in CF1 mice on day 16 following 20 mg/kg i.p. o.d. for 16 days.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Comparison of the hypolipidemic activity of cyclic vs. acyclic imides.
AID141909Agonist activity for murine PPAR delta receptor in transcriptional activation assay at 100 uM; IA means inactive2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID179764In vitro inhibitory activity against rat microsomal lipid peroxidation (m-LPO)1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID91242Agonist activity for Human PPAR delta receptor in transcriptional activation assay at 100 uM; IA means inactive2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1133146Modulation of liver to body weight ratio in sucrose-fed Sprague-Dawley rat at 0.4 mmol/kg, po bid for 7 days (Rvb = 3.88 to 4.06%)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1861624Hepatotoxicity in KM mouse assessed as reduction in plasma ALP level at 1.65 mmol/Kg, IG administered via gavage measured for 1 month by automated biochemical analyzer2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID189238Percent reduction of triglyceride level in plasma was evaluated 100 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID1123125Antilipidemic activity against Sprague-Dawley rat assessed as increase in liver to body weight at 0.4 mmol/kg, po twice daily for 7 days (Rvb = 3.96 +/- 0.20 mg/g)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID1149369Cholesterol-lowering activity in propylthiouracil-induced hypercholesterolemic rat model assessed as change in plasma cholesterol at 10 mg/kg administered intragastrically relative to control1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Potential hypolipidemic agents derived from 3-hydroxy-17,17-dimethylgona-1,3,5(10),8,11,13-hexaene.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID188889Percent increase in liver weight in plasma was evaluated 100 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID1362491Hepatoprotective activity in ICR mouse assessed as hepatocyte hyperplasia at 240 umol/kg/day administered po for 2 months by histopathological analysis2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1362476Toxicity in ICR mouse assessed as body weight at 240 umol/kg/day administered po for 2 months (Rvb = 36.8 +/- 0.70 g)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1751039Hepatotoxicity in Kunming mouse assessed as increase in plasma total protein level at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID338453Hypolipidemic activity in CF1 mouse assessed as serum cholesterol level at 150 mg/kg/day administered for 16 days measured on day 9 relative to control
AID196332Effect of compound was measured on serum total cholesterol in male Dawley rats at the dose of 0.4 mmol/kg (day+10).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1151069Antilipidemic activity in sucrose fed Sprague-Dawley rat model assessed as serum cholesterol level at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose (Rvb = 61.7 +/- 11.6 mg/dL)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID240312Effective concentration against human peroxisome proliferator activated receptor alpha in Gal4 transactivation assay2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID1151079Increase in liver to body weight ratio in sucrose-fed Sprague-Dawley rat model at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose (Rvb = 4.07 +/- 0.28 %)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID1144580Hypocholesterolemic activity in Sprague-Dawley rat assessed as serum cholesterol level at 10 mg/kg/day, po administered via intubation measured on day 10 by Liebermann-Burchard reaction (Rvb = 100%)1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Hypocholesterolemic activity of 1,3-bis(substituted phenoxy)-2-propanones.
AID189227Percent reduction of total cholesterol level in plasma was evaluated 100 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID170870Percent increase in liver weight in rats when a 50 mg/Kg dose was administered1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID196335Effect of compound was measured on serum total cholesterol in male Dawley rats at the dose of 0.4 mmol/kg (day+7).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1147167Hypolipidemic activity in Wistar rat assessed as reduction in plasma triglyceride level at 119 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID238856Binding affinity for human peroxisome proliferator activated receptor alpha2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID338452Hypolipidemic activity in CF1 mouse assessed as serum triglyceride level at 8 mg/kg/day, ip administered for 16 days measured on day 16 relative to control
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1130667Hypolipidemic activity in COBBS-CD rat assessed as reduction in serum triglyceride level at 0.1% administered with chow diet after 5 days relative to control1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
(Aryloxy)[p-(aryloxy)phenyl]- and (aryloxy)[p-(arylthio)phenyl]acetic acids and esters as hypolipidemic agents.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID171413Percent change in plasma total cholesterol in cholesterol-fed rats at 200 mg/kg dose given in a period of 3 days1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators.
AID186010Effect on liver weight was measured on treated rats at a dose of 0.05 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID1591810Up regulation of ApoA1 mRNA expression in human HepG2 cells at 100 uM by RT-PCR analysis relative to control2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208.
AID1149891Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum triglyceride level at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1861644Upregulation of Nrf2 protein expression in liver of KM mouse at 1.65 mmol/Kg, IG administered via gavage measured after 1 month by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1133132Drug metabolism in Ringer bicarbonate buffer assessed as hydrolysis at pH 7.4 measured after 60 mins1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID403777Antihyperlipidemic activity in olive oil-treated ddY mouse assessed as serum triglyceride level at 125 mg/kg, po after 4 hrs2005Journal of natural products, Sep, Volume: 68, Issue:9
Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).
AID1145556Hypolipidemic activity in albino Wistar Royal Hart rat assessed as change in plasma triglyceride level at 300 mg/kg, po for 6 days1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Synthesis and biological evaluation of substituted 2,2'-oxybis(propionic acid) derivatives and related compounds.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID427212Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 20 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID238857Binding affinity for human peroxisome proliferator activated receptor gamma2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID1151081Increase in liver weight in sucrose-fed Sprague-Dawley rat model at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose (Rvb = 11.76 +/- 1.32 gm)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID230119Ratio of plasma HDL cholesterol/total cholesterol at 200 g/kg for 3 days1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators.
AID189225Percent reduction of phospholipid level in plasma was evaluated 300 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID540235Phospholipidosis-negative literature compound
AID111631In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID427201Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) assessed as occupancy at a drug-protein molar ratio of 3:1 by NMR chemical shift perturbation method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID172356Effect on serum Triglycerides was determined in normal rats at a dose of 0.2 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID1673477Anti-inflammatory activity in mouse RAW264.7 cells assessed as decrease in ox-LDL induced inflammatory reaction by measuring decrease in TNF-alpha production at 10 to 50 uM preincubated for 10 mins followed by ox-LDL stimulation and measured after 24 hrs2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Anti-atherosclerosis effect of H
AID1362484Hepatoprotective activity in ICR mouse assessed as serum TBIL levels at 240 umol/kg/day administered po for 2 months (Rvb = 0.63 +/- 0.09 microM)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1673479Inhibition of macrophage foam cell formation in mouse RAW264.7 cells assessed as reduction in ox-LDL induced red lipid droplets formation at 10 uM preincubated for 10 mins followed by ox-LDL stimulation and measured after 24 hrs by oil red O staining base2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Anti-atherosclerosis effect of H
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID193997Effect of compound on liver TG levels in male Dawley rats at the dose of 0.4 mmol/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID677051Agonist activity at PPARalpha2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.
AID1362490Antioxidant activity in ICR mouse assessed as hepatic GSH to GSSG ratio at 240 umol/kg/day administered po for 2 months (Rvb = 16.4 +/- 2.34 No_unit)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1123130Antilipidemic activity against Sprague-Dawley rat assessed as increase in liver cyt b activity measured per mg of protein at 0.4 mmol/kg, po twice daily for 7 days (Rvb = 0.310 +/- 0.052 nmol)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID232525Effect of compound was measured on serum heparin-MnCl2 precipated ipoprotein Dawley rats at 0.4 mmol/kg dose(day+4).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1123129Antilipidemic activity against Sprague-Dawley rat assessed as increase in liver NADPH:cyt c reductase activity at 0.4 mmol/kg, po twice daily for 7 days (Rvb = 164 +/- 16.7 nmol/mg/min)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID1149376Hypolipidemic activity in normal rat assessed as reduction in triglyceride level at 0.2 % administered in diet for 5 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Potential hypolipidemic agents derived from 3-hydroxy-17,17-dimethylgona-1,3,5(10),8,11,13-hexaene.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID171550The compound was tested for % change in plasma triglycerides in normocholesterolemic rats at 0.2 % composition of dose with diet given in a period of 7 days1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators.
AID613545Toxicity in healthy rat assessed as incidence of drowsy state at 2000 to 7000 mg/kg, po measured after 2 to 6 hrs2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and biological evaluation of some novel cyclic-imides as hypoglycaemic, anti-hyperlipidemic agents.
AID1362486Antioxidant activity in ICR mouse assessed as serum MDA levels at 240 umol/kg/day administered po for 2 months (Rvb = 6 +/- 0.20 microM)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID383705Inhibition of serum triglyceride elevation in olive oil-treated ddY mouse at 500 mg/kg, po after 6 hrs2008Journal of natural products, May, Volume: 71, Issue:5
Perennisosides I-VII, acylated triterpene saponins with antihyperlipidemic activities from the flowers of Bellis perennis.
AID184860Minimum effective dose (MED) is the dose (mg/kg)that cause significant reduction in serum cholesterol of 30% compared to concurrent controls.1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Heterocyclic analogues of chlorcyclizine with potent hypolipidemic activity.
AID194689Activity to induce the elevation of alpha/beta cholesterol ratio in plasma lipids of male Wistar rats after po administration of 100 mg/kg/day1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
AID128639Hypolipidemic effects in CF1 male mice at a dose 150 mg/(kg day), ip,percent control of serum cholesterol was determined on day 91984Journal of medicinal chemistry, Jun, Volume: 27, Issue:6
Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogues.
AID1362493Hepatoprotective activity in ICR mouse assessed as midzonal mitosis at 240 umol/kg/day administered po for 2 months by histopathological analysis2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID172199Compound was tested for effect on liver weight after oral administration of 100 mg/kg in male rats.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID196336Effect of compound was measured on serum total cholesterol in male Dawley rats at the dose of 0.4 mmol/kg (day-1).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1751037Hepatotoxicity in Kunming mouse assessed as increase in plasma alanine aminotransferase level at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID128463Effect on Serum triglyceride levels on CF1 male mice at a dose of 20 (mg/kg)/day after 14 days1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Hypolipidemic activity of phthalimide derivatives. 2. N-phenylphthalimide and derivatives.
AID1673473Anti-atherosclerotic activity in mouse RAW264.7 cells assessed as decrease in ox-LDL induced intracellular lipid accumulation by measuring reduction in free cholesterol level at 10 to 50 uM preincubated for 10 mins followed by ox-LDL stimulation and measu2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Anti-atherosclerosis effect of H
AID188378Hypolipidemic activity was expressed as percent decrease in serum cholesterol1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1861638Hepatotoxicity in KM mouse assessed as large areas of hepatocytes swelling at 1.65 mmol/Kg, IG administered via gavage by H and E staining based analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1151071Antilipidemic activity in sucrose fed Sprague-Dawley rat model assessed as serum triglyceride level at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose (Rvb = 91.9 +/- 19.8 mg/dL)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID1751046Hepatotoxicity in Kunming mouse assessed as large areas of hepatocyte swelling, necrosis, loose cytoplasm, nuclear degeneration and dissolution at 300 mg/kg, ig for 1 month by H and E staining based analysis2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1861642Hepatotoxicity in KM mouse assessed as appearance of loose cytoplasm at 1.65 mmol/Kg, IG administered via gavage by H and E staining based analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID407366Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1123128Antilipidemic activity against Sprague-Dawley rat assessed as increase in liver ethylmorphine N-demethylase activity measured as HCHO formation per mg/min at 0.4 mmol/kg, po twice daily for 7 days (Rvb = 6.48 +/- 0.70 nmol)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID1751049Upregulation of p-NF-kB-p65 protein expression in Kunming mouse liver at 300 mg/kg, ig for 1 month by western blot analysis2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID503325Activation of c-Jun expressed in HEK293 cells assessed as induction of protein interaction with Pin1 by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1147531Inhibition of cholesterol biosynthesis in Ad Lib fed Wistar rat liver assessed as sodium [1-14C]acetate incorporation at 261 mg/kg/day administered through diet for 7 days measured 1 hr after labeled acetate challenge by liquid scintillation spectrometry 1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID1133172Antilipidemic activity in normal Sprague-Dawley rat assessed at 0.4 mmol/kg, po bid for 7 days1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID189353Percent reduction of triglyceride level in plasma was evaluated 30 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID194703Activity to induce the elevation of triglycerides in plasma lipids of male Wistar rats after po administration of 100 mg/kg/day1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
AID173219Percent change in total cholesterol concentration in serum from hypercholesterolemic rats at dose 200 mg/kg (po)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID1151095Antilipidemic activity in triton WR-1339-induced hyperlipidemic Sprague-Dawley rat model assessed as reduction of plasma lipid level at 0.124 mM/kg measured 48 hrs after triton WR-1339 challenge1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID194558Activity to induce the elevation of HDL(High Density Lipoproteins)-Cholesterol in plasma lipids of male Wistar rats after po administration of 100 mg/kg/day1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
AID196327Effect of compound was measured on serum alpha-lipoprotein in male Dawley rats at the dose of 0.4 mmol/kg (day+10).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1861626Induction of oxidative stress in KM mouse assessed as reduction in SOD level in plasma at 1.65 mmol/Kg, IG administered via gavage measured for 1 month2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID240313Effective concentration against human peroxisome proliferator activated receptor gamma in Gal4 transactivation assay2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID1474085AUC in human at 2 g, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID427202Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) assessed as occupancy at a drug-protein molar ratio of 3:1 by NMR chemical shift perturbation method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID1151075Antilipidemic activity in sucrose-fed Sprague-Dawley rat model assessed as reduction of liver triglyceride level at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID1133143Modulation of cholesterol level in sucrose-fed Sprague-Dawley rat liver at 0.4 mmol/kg, po bid for 7 days (Rvb = 1.81 to 2.17 mg/g)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID188887Percent decrease in serum cholesterol (Cho) after 7 days at 0.05 percent in the diet of SD male rats in comparison to control animals1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and hypolipidemic activities of 5-thienyl-4-oxazoleacetic acid derivatives.
AID1133142Antilipidemic activity in sucrose-fed Sprague-Dawley rat assessed as serum triglyceride level at 0.4 mmol/kg, po bid for 7 days measured on day 7 (Rvb = 115.6 +/- 19.4 mg/dL)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID141903Agonist activity for murine PPAR alpha receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID420697Reduction of plasma triglyceride level in human2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID1362477Hypolipidemic activity in Triton WR 1339-induced acute hyperlipidemic ICR mouse model assessed as decrease in plasma triglyceride levels at 240 umol/kg, ig for one week followed by Triton WR 1339 challenge on day 6 measured after 24 hrs2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID191250Compound was tested for hypolipidemic activity in male rats, cholesterol level was determined in serum at 30 mg/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID1751058Hepatotoxicity in Kunming mouse assessed as cell infiltration in central vein and inflammatory cell infiltration at 300 mg/kg, ig for 1 month by H and E staining based analysis2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID116864Reduction in serum cholesterol in CF1 mice on day 14 following 20 mg/kg i.p. o.d. for 16 days.1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Comparison of the hypolipidemic activity of cyclic vs. acyclic imides.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1751069Upregulation of HO-1 protein expression in Kunming mouse liver at 300 mg/kg, ig for 1 month by western blot analysis2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID190950Effect on serum Triglycerides was measured on control rats at a dose of 0.05 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID1133145Modulation of HMG-CoA reductase activity in sucrose-fed Sprague-Dawley rat liver assessed as mevalonic acid formation using DL-3-hydroxy-3-methylglutaryl-3-14C-CoA as substrate at 0.4 mmol/kg, po bid for 7 days (Rvb = 8.27 to 8.3 nmol/mg/hr)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID189221Percent reduction of phospholipid level in plasma was evaluated 100 mg/kg in rat1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
N-phenylpiperazine derivatives with hypocholesterolemic activity.
AID1133152Modulation of NADPH-cytochrome c reductase activity in sucrose-fed Sprague-Dawley rat liver microsomes assessed as cytochrome c reduction at 0.4 mmol/kg, po bid for 7 days (Rvb = 202.5 +/- 27.9 nmol/mg/min)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID190922Hypolipidemic activity was determined in male rats, and high-density lipoprotein level was determined at 30 mg/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID1861645Upregulation of HO-1 protein expression in liver of KM mouse at 1.65 mmol/Kg, IG administered via gavage measured after 1 month by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID383703Inhibition of serum triglyceride elevation in olive oil-treated ddY mouse at 500 mg/kg, po after 2 hrs2008Journal of natural products, May, Volume: 71, Issue:5
Perennisosides I-VII, acylated triterpene saponins with antihyperlipidemic activities from the flowers of Bellis perennis.
AID1130671Hypolipidemic activity in COBBS-CD rat assessed as reduction in serum triglyceride level at 0.3% administered with chow diet after 5 days relative to control1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
(Aryloxy)[p-(aryloxy)phenyl]- and (aryloxy)[p-(arylthio)phenyl]acetic acids and esters as hypolipidemic agents.
AID232526Effect of compound was measured on serum heparin-MnCl2 precipated ipoprotein Dawley rats at 0.4 mmol/kg dose(day+7).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID111638In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 50 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1123131Antilipidemic activity against Sprague-Dawley rat assessed as increase in liver cyt P-450 activity measured per mg of protein at 0.4 mmol/kg, po twice daily for 7 days (Rvb = 0.833 +/- 0.0644 nmol)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID232517Effect of compound on liver to body weight ratio in male Dawley rats at the dose of 0.4 mmol/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID128449Effect on Serum cholesterol levels on CF1 male mice at a dose of 20 (mg/kg)/day after 9 days1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Hypolipidemic activity of phthalimide derivatives. 2. N-phenylphthalimide and derivatives.
AID172908Percent change in high density lipoproteins cholesterol concentration in serum from hypercholesterolemic rats at dose 200 mg/kg (po)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
AID196333Effect of compound was measured on serum total cholesterol in male Dawley rats at the dose of 0.4 mmol/kg (day+14).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID403775Antihyperlipidemic activity in olive oil-treated ddY mouse assessed as serum triglyceride level at 250 mg/kg, po after 2 hrs2005Journal of natural products, Sep, Volume: 68, Issue:9
Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).
AID1151065Antilipidemic activity in purina chow fed Sprague-Dawley rat assessed as reduction of serum cholesterol level at 0.124 mM/kg relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID338455Hypolipidemic activity in CF1 mouse assessed as serum triglyceride level at 150 mg/kg/day administered for 16 days measured on day 16 relative to control
AID1751040Hepatotoxicity in Kunming mouse assessed as induction of oxidative stress by measuring decrease in plasma superoxide dismutase level at 300 mg/kg, ig for 1 month2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1751032Hypolipidemic activity in TritonWR1339-induced hyperlipidemic Kunming mouse model assessed as reduction in plasma TG level at 0.362 mmol/kg, ig administered for 7 days2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID232523Effect of compound was measured on serum heparin-MnCl2 precipated ipoprotein Dawley rats at 0.4 mmol/kg dose(day+10).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID196334Effect of compound was measured on serum total cholesterol in male Dawley rats at the dose of 0.4 mmol/kg (day+4).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID190952Effect on serum Triglycerides was measured on treated rats at a dose of 0.05 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID1861641Hepatotoxicity in KM mouse assessed as blurred edge dissolution at 1.65 mmol/Kg, IG administered via gavage by H and E staining based analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID128448Effect on Serum cholesterol levels on CF1 male mice at a dose of 20 (mg/kg)/day after 16 days1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Hypolipidemic activity of phthalimide derivatives. 2. N-phenylphthalimide and derivatives.
AID1147353Increase in liver weight in Wistar rat at 1693 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID427204Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 42 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID383701Inhibition of serum triglyceride elevation in olive oil-treated ddY mouse at 250 mg/kg, po after 4 hrs2008Journal of natural products, May, Volume: 71, Issue:5
Perennisosides I-VII, acylated triterpene saponins with antihyperlipidemic activities from the flowers of Bellis perennis.
AID232524Effect of compound was measured on serum heparin-MnCl2 precipated ipoprotein Dawley rats at 0.4 mmol/kg dose(day+14).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1362480Antioxidant activity assessed as hydroxyl radical scavenging activity after 60 mins2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID699017Transactivation of PPARalpha expressed in human HepG2 cells assessed as Sult2a1 expression at 10 uM by luciferase reporter gene assay relative to vehicle-treated control2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists.
AID1861639Hepatotoxicity in KM mouse assessed as infiltration of inflammatory cells at 1.65 mmol/Kg, IG administered via gavage by H and E staining based analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID190923Hypolipidemic activity was determined in male rats, cholesterol was determined in low-density lipoproteins at 100 mg/kg1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Hypolipidemic activity of rifamycin derivatives.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID196343Effect of compound was measured on serum total triglycerides in male Dawley rats at the dose of 0.4 mmol/kg (day-1).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1362487Antioxidant activity in ICR mouse assessed as serum CAT levels at 240 umol/kg/day administered po for 2 months (Rvb = 2.83 +/- 0.22 U/ml)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1751068Upregulation of Nrf2 protein expression in Kunming mouse liver nucleus at 300 mg/kg, ig for 1 month by western blot analysis2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1861629Induction of oxidative stress in KM mouse assessed as increase in MDA level in plasma at 1.65 mmol/Kg, IG administered via gavage measured for 1 month2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1751045Hepatotoxicity in Kunming mouse assessed as induction of inflammatory response by measuring upregulation of IL-6 level in liver at 300 mg/kg, ig for 1 month by western blot analysis2021Bioorganic & medicinal chemistry letters, 07-15, Volume: 44The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
AID1673476Antioxidant activity in mouse RAW264.7 cells assessed as reduction in ox-LDL induced oxidative stress by measuring increase in SOD level at 10 to 50 uM preincubated for 10 mins followed by ox-LDL stimulation and measured after 24 hrs2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Anti-atherosclerosis effect of H
AID180075Hypolipidemic effects in rat plasma high density lipoprotein cholesterol (HDLC) by peroral administration at 100 mg/kg dose1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID172205Compound was tested for effect on serum VLDL after oral administration of 100 mg/kg in male rats1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
AID109738Hypoglycemic activity at dose 50 mg/Kg in KK-mice after peroral administration1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1362481Hepatoprotective activity in ICR mouse assessed as serum AST levels at 240 umol/kg/day administered po for 2 months (Rvb = 107.25 +/- 2.77 U/L)2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
AID1861622Hepatotoxicity in KM mouse assessed as reduction in plasma AST level at 1.65 mmol/Kg, IG administered via gavage measured for 1 month by automated biochemical analyzer2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1151067Antilipidemic activity in purina chow fed Sprague-Dawley rat assessed as reduction of serum triglyceride level at 0.124 mM/kg relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID1130664Hypolipidemic activity in COBBS-CD rat assessed as reduction in serum sterol level at 0.1% administered with chow diet after 5 days relative to control1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
(Aryloxy)[p-(aryloxy)phenyl]- and (aryloxy)[p-(arylthio)phenyl]acetic acids and esters as hypolipidemic agents.
AID503341Inhibition of Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID420698Increase of plasma HDL cholesterol level in human2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID427210Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) at 25 deg C by fluorimetric assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1861619Toxicity in KM mouse assessed as reduction in body weight at 1.65 mmol/Kg, IG administered via gavage measured for 1 month2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1133150Modulation of cytochrome b5 activity in sucrose-fed Sprague-Dawley rat liver microsomes at 0.4 mmol/kg, po bid for 7 days measured per mg of protein (Rvb = 0.185 to 0.213 nmol)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID403776Antihyperlipidemic activity in olive oil-treated ddY mouse assessed as serum triglyceride level at 500 mg/kg, po after 2 hrs2005Journal of natural products, Sep, Volume: 68, Issue:9
Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).
AID196331Effect of compound was measured on serum alpha-lipoprotein in male Dawley rats at the dose of 0.4 mmol/kg (day14).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID1151083Increase in microsomal protein level in sucrose-fed Sprague-Dawley rat model at 0.4 mmol/kg, po bid administered for 7 days measured after 12 hrs post last dose (Rvb = 32.7 +/- 2.2 mg/gm)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Diethyl (4baalpha,4calpha,9aalpha,9balpha)-3,6-dichlorocyclobuta[1,2-b:3,4-b']bisbenzofuran-9a,9b(4bH,4cH)-dicarboxylate: the cis,syn photodimer of ethyl 5-chlorobenzofuran-2-carboxylate, an analogue related to the antilipidemic drug clofibrate.
AID111639In vivo activity against triglycerides (TG) by Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 50 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID111636In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID189961Hypolipidemic effect in rat plasma Total cholesterol (TC) by peroral administration at 100 mg/kg dose1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID194696Activity to induce the elevation of phospholipids in plasma lipids of male Wistar rats after po administration of 100 mg/kg/day1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID326599Agonist activity at mouse PPARalpha receptor in monkey COS7 cells assessed as activation of CAT reporter gene at 150 uM by transactivation assay relative to Wy,14-6432008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID383699Inhibition of serum triglyceride elevation in olive oil-treated ddY mouse at 125 mg/kg, po after 6 hrs2008Journal of natural products, May, Volume: 71, Issue:5
Perennisosides I-VII, acylated triterpene saponins with antihyperlipidemic activities from the flowers of Bellis perennis.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID93033Agonist activity for Human PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID196340Effect of compound was measured on serum total triglycerides in male Dawley rats at the dose of 0.4 mmol/kg (day+4).1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid.
AID111628In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1861635Induction of inflammation in KM mouse assessed as upregulation of IL-6 expression in liver tissue at 1.65 mmol/Kg, IG administered via gavage measured for 1 month by Western blot analysis2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Optimization of clofibrate with O-desmethyl anetholtrithione lead to a novel hypolipidemia compound with hepatoprotective effect.
AID1147537Inhibition of fatty acid biosynthesis in meal fed Wistar rat liver assessed as sodium [1-14C]acetate incorporation at 188 mg/kg/day administered through diet for 7 days measured 1 hr after labeled acetate challenge by liquid scintillation spectrometry (Rv1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID403778Antihyperlipidemic activity in olive oil-treated ddY mouse assessed as serum triglyceride level at 250 mg/kg, po after 4 hrs2005Journal of natural products, Sep, Volume: 68, Issue:9
Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).
AID1133135Antilipidemic activity in Triton WR-1339-induced hyperlipidemic Sprague-Dawley rat model assessed as plasma cholesterol level at 0.124 mg/kg, po (Rvb = 166 +/- 17.8 mg/dL)1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
AID1149890Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum cholesterol level at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID190951Effect on serum Triglycerides was measured on control rats at a dose of 0.5 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID1147166Hypolipidemic activity in Wistar rat assessed as reduction in plasma triglyceride level at 304 umol/kg/day administered through diet for 10 days1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID111644In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 300 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1123122Antilipidemic activity against Sprague-Dawley rat assessed as liver cholesterol level per gram of tissue at 0.4 mmol/kg, po twice daily for 7 days (Rvb = 2.96 +/- 0.42 mg)1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Synthesis and pharmacological evaluation of cis-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-1-ones. Tricyclic analogues related to the antilipidemic drug clofibrate.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID186024Hypolipidemic effects in rat fed a normal diet by peroral administration at 100 mg/kg dose.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
AID403779Antihyperlipidemic activity in olive oil-treated ddY mouse assessed as serum triglyceride level at 500 mg/kg, po after 4 hrs2005Journal of natural products, Sep, Volume: 68, Issue:9
Floratheasaponins A-C, acylated oleanane-type triterpene oligoglycosides with anti-hyperlipidemic activities from flowers of the tea plant (Camellia sinensis).
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,555)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902558 (71.95)18.7374
1990's538 (15.13)18.2507
2000's298 (8.38)29.6817
2010's139 (3.91)24.3611
2020's22 (0.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.57 (24.57)
Research Supply Index8.34 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index89.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials314 (8.14%)5.53%
Reviews295 (7.64%)6.00%
Case Studies103 (2.67%)4.05%
Observational0 (0.00%)0.25%
Other3,147 (81.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00000482]Phase 30 participants Interventional1965-04-30Completed
[NCT00000483]0 participants Interventional1981-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]